

# CITATION REPORT

List of articles citing

## The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

DOI: 10.1182/blood.v92.7.2322  
Blood, 1998, 92, 2322-2333.

**Source:** <https://exaly.com/paper-pdf/29915870/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2319	Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. <b>1992</b> , 34, 417		
2318	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. <b>1992</b> , 33, 239		
2317	Transplantation in first remission of acute myeloid leukemia. <b>1998</b> , 339, 1698-700		21
2316	Diagnosis of Childhood Acute Myeloid Leukemia. <b>1999</b> , 19, 187-238		9
2315	Microsatellite Instability and p53 Mutations Are Associated With Abnormal Expression of the MSH2 Gene in Adult Acute Leukemia. <i>Blood</i> , <b>1999</b> , 94, 733-740	2.2	104
2314	Acute myeloid leukemia relapsing as gynecomastia. <b>1999</b> , 36, 191-4		11
2313	Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. <b>1999</b> , 104, 307-12		24
2312	The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. <b>1999</b> , 106, 296-308		164
2311	c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. <b>1999</b> , 105, 894-900		201
2310	The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. <b>1999</b> , 106, 591-613		69
2309	Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance. <b>1999</b> , 106, 578-90		45
2308	Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. <b>1999</b> , 107, 80-5		54
2307	A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. <b>1999</b> , 107, 69-79		336
2306	Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty-year experience (1975 to 1996). <b>1999</b> , 29, 726-30		3
2305	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RAR $\alpha$ rearrangement in newly diagnosed AML. <b>1999</b> , 105, 198-207		40
2304	A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. <b>1999</b> , 13, 1491-6		18
2303	Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias. <b>1999</b> , 13, 1770-5		19

2302	Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. <b>1999</b> , 13, 1735-40	32
2301	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. <b>1999</b> , 13, 1901-28	920
2300	Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. <b>1999</b> , 13, 1943-53	65
2299	Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. <b>1999</b> , 24, 735-9	31
2298	Acute myeloid leukemia. <b>1999</b> , 341, 1051-62	1160
2297	Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. <b>1999</b> , 78, 251-64	52
2296	Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML. <b>1999</b> , 78, 265-9	18
2295	Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. <b>1999</b> , 112, 15-20	32
2294	Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. <b>1999</b> , 27, 1822-30	39
2293	Cytogenetics and molecular genetics of childhood leukemia. <b>1999</b> , 17, 91-105	39
2292	Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia. <b>1999</b> , 13, 987-1015, vi-vii	11
2291	The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease. <b>2000</b> , 5, 369-81	11
2290	Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. <b>2000</b> , 18, 780-7	69
2289	Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. <b>2000</b> , 111, 1051-6	56
2288	Recent advances in the treatment of acute leukemia: 1999. <b>2000</b> , 7, 205-11	10
2287	Acute myeloid leukemia: therapeutic indications. <b>2000</b> , 7, 333-8	10
2286	Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. <b>2000</b> , 88, 2037-41	20
2285	A DNA probe combination for improved detection of MLL/11q23 breakpoints by double-color interphase-FISH in acute leukemias. <b>2000</b> , 28, 14-22	46

2284	Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation. <b>2000</b> , 29, 333-338	48
2283	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <b>2000</b> , 28, 318-28	47
2282	Differential display as an approach to study differentiation and differentiation therapy in AML. <b>2000</b> , 18, 129-140	3
2281	The management of patients with leukaemia: the role of cytogenetics in this molecular era. <b>2000</b> , 108, 19-30	25
2280	Screening for mutations of Bcl10 in leukaemia. <b>2000</b> , 109, 611-5	9
2279	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <b>2000</b> , 110, 308-14	54
2278	Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. <b>2000</b> , 26, 397-404	168
2277	Molecular genetics in acute leukemia. <b>2000</b> , 14, 513-7	71
2276	Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. <b>2000</b> , 14, 226-31	69
2275	Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. <b>2000</b> , 14, 364-8	24
2274	Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. <b>2000</b> , 14, 636-41	45
2273	Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. <b>2000</b> , 14, 675-83	233
2272	Reported cryptic rearrangements of CBFbeta-MYH11 in acute myeloid leukaemia are not due to false priming of contaminating DNA. <b>2000</b> , 14, 944-5	3
2271	Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. <b>2000</b> , 14, 1031-8	57
2270	Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. <b>2000</b> , 14, 889-97	73
2269	Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993. <b>2000</b> , 14, 1039-43	13
2268	Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. <b>2000</b> , 14, 1201-7	61
2267	High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. <b>2000</b> , 14, 1191-6	13

2266	Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. <b>2000</b> , 14, 1711-7	37
2265	MLL amplification in acute leukaemia: a United Kingdom Cancer Cytogenetics Group (UKCCG) study. <b>2000</b> , 14, 1885-91	49
2264	Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD). <b>2000</b> , 14, 1861-6	7
2263	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. <b>2000</b> , 111, 190-195	7
2262	Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1/MTG8-fused gene-positive acute myelogenous leukaemia. <b>2000</b> , 111, 570-579	1
2261	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <b>2000</b> , 111, 801-806	8
2260	Cytogenetically cryptic AML1/ETO and CBFMYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. <b>2000</b> , 111, 1051-1056	3
2259	Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. <b>2000</b> , 24, 481-6	13
2258	Identification of acute myeloid leukemia patients with diminished expression of CD13 myeloid transcripts by competitive reverse transcription polymerase chain reaction (RT-PCR). <b>2000</b> , 24, 497-506	4
2257	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. <b>2000</b> , 24, 567-74	56
2256	Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. <b>2000</b> , 24, 401-9	10
2255	Apparently unrelated clones shown by spectral karyotyping to represent clonal evolution of cryptic t(10;11)(p13;q23) in a patient with acute monoblastic leukemia. <b>2000</b> , 120, 105-10	12
2254	Acute myeloid leukemia in adults. <b>2000</b> , 1, 9-17	17
2253	Molecular biology of leukemia. <b>2000</b> , 2, 123-31	1
2252	Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. <b>2000</b> , 2, 529-38	7
2251	Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). <b>2000</b> , 79, 374-7	36
2250	Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. <b>2000</b> , 79, 533-42	17
2249	Karyotypic analysis predicts outcome of preresmission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , <b>2000</b> , 96, 4075-4083	2.2 1304

2248	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. <i>Blood</i> , <b>2000</b> , 96, 870-877	2.2	108
2247	Anticorresponding p15 promoter methylation and microsatellite instability in acute myeloblastic leukemia. <i>Blood</i> , <b>2000</b> , 96, 2002-2002	2.2	5
2246	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. <i>Blood</i> , <b>2000</b> , 96, 2002-2003	2.2	6
2245	Multifaceted Approach to the Diagnosis and Classification of Acute Leukemias. <b>2000</b> , 46, 1252-1259		25
2244	Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. <b>2000</b> , 40, 67-77		55
2243	A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission. <b>2000</b> , 104, 144-7		1
2242	Alterations of the AML1 transcription factor in human leukemia. <b>2000</b> , 11, 347-60		45
2241	Cytogenetic analysis in leukemia and lymphoma: an introduction. <b>2000</b> , 37, 315-9		13
2240	White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice. <b>2000</b> , 355, 1447-53		4
2239	SIGNIFICANCE OF MONOSOMY 7 IN MYELOID LEUKEMIAS IN CHILDREN. <b>2000</b> , 19, 235-250		0
2238	Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. <b>2000</b> , 18, 768-80		43
2237	Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. <b>2000</b> , 18, 139-47		56
2236	Laboratory diagnosis of acute myeloid leukaemia. <b>2001</b> , 14, 1-17		4
2235	Clinical importance of cytogenetics in acute myeloid leukaemia. <b>2001</b> , 14, 19-47		140
2234	Treatment of acute myeloid leukaemia in younger patients. <b>2001</b> , 14, 95-118		8
2233	The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. <b>2001</b> , 14, 497-529		112
2232	The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. <b>2001</b> , 3, 175-88		7
2231	CD133 (AC133) expression on AML cells and progenitors. <b>2001</b> , 3, 449-59		32

2230	Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. <b>2001</b> , 28, 807-15		33
2229	Current status and perspectives of therapy for acute myeloid leukemia. <b>2001</b> , 38, 3-9		16
2228	Postremission therapy in adults with acute myeloid leukemia. <b>2001</b> , 38, 17-23		8
2227	Leucemias agudas mieloides. Manifestaciones clínicas, diagnóstico, pronóstico y estrategias terapéuticas. <b>2001</b> , 8, 2890-2896		
2226	Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. <b>2001</b> , 42, 57-65		9
2225	Treatment of acute leukemia in children: recent advances and future challenges. <b>2001</b> , 1, 479-86		
2224	Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. <b>2001</b> , 41, 493-500		5
2223	MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML. <b>2001</b> , 40, 613-23		6
2222	Therapy of acute myeloid leukemia. <b>2001</b> , 8, 62-78		21
2221	Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. <b>2001</b> , 19, 2482-92		86
2220	Meeting report of the 2000 International Congress of Pediatric Hematology/Oncology: Shanghai Children's Medical Center, Shanghai, People's Republic of China, October 18-20, 2000. <b>2001</b> , 23, 533-47		
2219	Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. <i>Blood</i> , <b>2001</b> , 97, 1422-6	2.2	114
2218	Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. <i>Blood</i> , <b>2001</b> , 98, 565-72	2.2	148
2217	The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , <b>2001</b> , 98, 1312-20	2.2	742
2216	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , <b>2001</b> , 98, 2200-9	2.2	117
2215	JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. <i>Blood</i> , <b>2001</b> , 97, 502-8	2.2	68
2214	Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. <i>Blood</i> , <b>2001</b> , 97, 805-8	2.2	54
2213	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. <i>Blood</i> , <b>2001</b> , 98, 3541-53	2.2	110

2212	Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. <i>Blood</i> , <b>2001</b> , 98, 405-13	2.2	25
2211	A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. <i>Blood</i> , <b>2001</b> , 98, 1166-73		289
2210	Loss of heterozygosity in childhood de novo acute myelogenous leukemia. <i>Blood</i> , <b>2001</b> , 98, 1188-94	2.2	16
2209	Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , <b>2001</b> , 98, 1302-11	2.2	370
2208	Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. <i>Blood</i> , <b>2001</b> , 98, 1714-20	2.2	116
2207	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , <b>2001</b> , 98, 1746-51	2.2	271
2206	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. <i>Blood</i> , <b>2001</b> , 98, 1752-9	2.2	1209
2205	Acute Myelogenous Leukaemia in Patients 60 Years and Older: A Retrospective Analysis from St Bartholomew's Hospital 1969-1999. <b>2001</b> , 6, 163-75		1
2204	Tumours of the Immune System. <b>2001</b> ,		
2203	Spectral karyotyping (SKY) in hematological neoplasia. <b>2001</b> , 4259, 56		
2202	Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. <b>2001</b> , 80, 334-9		20
2201	Klassische und molekulare Zytogenetik in der Hämatologie und Onkologie. <b>2001</b> , 7, 1028-1038		
2200	Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. <b>2001</b> , 112, 118-26		137
2199	A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. <b>2001</b> , 112, 127-37		96
2198	EV11 expression in acute myeloid leukaemia. <b>2001</b> , 112, 208-11		45
2197	Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth. <b>2001</b> , 113, 120-5		9
2196	Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. <b>2001</b> , 113, 727-36		16
2195	Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. <b>2001</b> , 113, 763-71		148



2194	Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. <b>2001</b> , 113, 983-8	303
2193	Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. <b>2001</b> , 114, 307-12	33
2192	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. <b>2001</b> , 115, 25-33	63
2191	Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. <b>2001</b> , 115, 612-5	25
2190	The leukemic effect of anticholinesterases. <b>2001</b> , 25, 1027-8	2
2189	Therapy-related leukemia associated with alkylating agents. <b>2001</b> , 36, 536-40	45
2188	Molecular analysis of fusion transcripts in childhood acute myeloid leukemia in Taiwan. <b>2001</b> , 37, 555-6	14
2187	Therapeutic options for acute myelogenous leukemia. <b>2001</b> , 92, 1059-73	79
2186	Recent advances in the treatment of AML. <b>2001</b> , 19, 107-18	2
2185	Detection and quantification of CBFβ/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. <b>2001</b> , 30, 342-8	33
2184	Cross-species color banding in ten cases of myeloid malignancies with complex karyotypes. <b>2001</b> , 30, 15-24	16
2183	Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?. <b>2001</b> , 30, 261-6	4
2182	Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review. <b>2001</b> , 73, 93-9	15
2181	Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay (M-TEL). <b>2001</b> , 7, 497-501	63
2180	Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. <b>2001</b> , 28, 349-54	22
2179	Age cohort subgroups in adult acute myeloid leukaemia studies--the population perspective. <b>2001</b> , 15, 188-9	6
2178	Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF. <b>2001</b> , 15, 377-84	15
2177	Treatment of leukemic relapse after allogeneic stem cell transplantation with cytoreductive chemotherapy and/or immunotherapy or second transplants. <b>2001</b> , 15, 355-61	18

2176	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. <b>2001</b> , 15, 903-9	57
2175	Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. <b>2001</b> , 15, 1046-53	14
2174	Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. <b>2001</b> , 15, 1326-30	30
2173	Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. <b>2001</b> , 15, 1892-7	38
2172	Chromosome translocations: dangerous liaisons revisited. <b>2001</b> , 1, 245-50	220
2171	Comparative genomic hybridization-aided unraveling of complex karyotypes in human hematopoietic neoplasias. <b>2001</b> , 124, 1-6	15
2170	The application of comparative genomic hybridization as an additional tool in the chromosome analysis of acute myeloid leukemia and myelodysplastic syndromes. <b>2001</b> , 126, 26-33	30
2169	Acute myeloid leukemia with t(5;18)(q35;q21). <b>2001</b> , 127, 71-3	5
2168	Karyotype and age in acute myeloid leukemia. Are they linked?. <b>2001</b> , 126, 155-61	50
2167	Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia. <b>2001</b> , 127, 85-8	13
2166	Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2). a four-way variant of t(8;21). <b>2001</b> , 128, 104-7	29
2165	The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. <b>2001</b> , 130, 160-5	48
2164	17q21-qter trisomy is an indicator of poor prognosis in acute myelogenous leukemia. <b>2001</b> , 124, 12-5	6
2163	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. <b>2001</b> , 25, 23-32	20
2162	De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy. <b>2001</b> , 25, 33-38	9
2161	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. <b>2001</b> , 25, 685-92	10
2160	Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. <b>2001</b> , 66, 160-7	11
2159	Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse. <b>2001</b> , 67, 207-20	5

2158	FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. <b>2001</b> , 67, 221-9		7
2157	Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. <b>2001</b> , 98, 11592-7		210
2156	Acute Leukemias VIII. <b>2001</b> ,		1
2155	Retinal abnormalities in newly diagnosed adult acute myeloid leukemia. <b>2001</b> , 105, 197-203		13
2154	Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien. <b>2001</b> , 25, 512-532		
2153	Realistic pathologic classification of acute myeloid leukemias. <b>2001</b> , 115, 552-60		27
2152	Therapy related leukemias: susceptibility, prevention and treatment. <b>2001</b> , 41, 255-76		99
2151	Acute myeloid leukemia. <b>2001</b> , 2001, 62-86		90
2150	A systematic overview of chemotherapy effects in acute myeloid leukaemia. <b>2001</b> , 40, 231-52		48
2149	Erythroleukaemia in the north of England: a population based study. <b>2001</b> , 54, 608-12		15
2148	Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy. <b>2001</b> , 42, 913-22		2
2147	Detection of minimal residual disease. <b>2001</b> , 82, 133-85		40
2146	Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes. <b>2001</b> , 42, 747-56		17
2145	Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. <i>Blood</i> , <b>2001</b> , 98, 3569-74	2.2	224
2144	Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). <i>Blood</i> , <b>2002</b> , 100, 618-26	2.2	116
2143	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , <b>2002</b> , 100, 4325-36	2.2	1287
2142	Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. <b>2002</b> , 11, 349-57		17
2141	Chromosome 19 abnormalities are commonly seen in AML, M7. <i>Blood</i> , <b>2002</b> , 100, 3838; author reply 3838-9		15

2140	Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. <b>2002</b> , 20, 2480-5		87
2139	Acute myeloid leukemia in children: a review of risk factors and recent trials. <b>2002</b> , 20, 1027-37		3
2138	Acute myeloid leukemia. <b>2002</b> , 2002, 73-110		68
2137	A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. <i>Blood</i> , <b>2002</b> , 99, 3517-23	2.2	148
2136	Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. <b>2002</b> , 99, 10008-13		215
2135	The World Health Organization (WHO) classification of the myeloid neoplasms. <i>Blood</i> , <b>2002</b> , 100, 2292-302		1637
2134	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. <i>Blood</i> , <b>2002</b> , 99, 4326-35	2.2	1353
2133	Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). <b>2002</b> , 69, 193-9		13
2132	Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). <i>Blood</i> , <b>2002</b> , 100, 2717-23	2.2	436
2131	[Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. <b>2002</b> , 214, 179-87		12
2130	[Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results]. <b>2002</b> , 127, 2186-92		5
2129	The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. <b>2002</b> , 43, 583-6		12
2128	Chromosome 11q deletion in myeloid malignancies. <b>2002</b> , 16, 953-5		9
2127	[Diagnostics and therapy of acute myeloid leukemia]. <b>2002</b> , 127, 2208-13		
2126	Is there an upper age limit for bone marrow transplantation?. <b>2002</b> , 29, 277-84		33
2125	Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. <b>2002</b> , 16, 1176-81		90
2124	Screening for core binding factor gene rearrangements in acute myeloid leukemia. <b>2002</b> , 16, 964-9		22
2123	Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. <b>2002</b> , 16, 368-75		52

2122	Therapy of secondary leukemia. <b>2002</b> , 16, 748-50		18
2121	Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. <b>2002</b> , 16, 776-84		88
2120	Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. <b>2002</b> , 13, 1621-7		40
2119	Favorable impact of the t(9;11) in childhood acute myeloid leukemia. <b>2002</b> , 20, 2302-9		139
2118	Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins. <b>2002</b> , 99, 15434-9		53
2117	Progress and controversies in the treatment of pediatric acute myelogenous leukemia. <b>2002</b> , 9, 353-60		30
2116	The challenge of acute myeloid leukemia in older patients. <b>2002</b> , 14, 24-30		41
2115	Megadose of hematopoietic stem cells for haploidentical transplants. <b>2002</b> , 7, 294-298		
2114	Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. <i>Blood</i> , <b>2002</b> , 100, 3352-60	2.2	54
2113	Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. <i>Blood</i> , <b>2002</b> , 99, 372-4	2.2	29
2112	Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. <i>Blood</i> , <b>2002</b> , 99, 1909-12		204
2111	A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay. <i>Blood</i> , <b>2002</b> , 99, 2526-31	2.2	62
2110	Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. <i>Blood</i> , <b>2002</b> , 99, 2985-91	2.2	78
2109	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. <i>Blood</i> , <b>2002</b> , 100, 2393-8	2.2	255
2108	Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , <b>2002</b> , 100, 2703-7	2.2	97
2107	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , <b>2002</b> , 100, 4372-80	2.2	690
2106	Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. <i>Blood</i> , <b>2002</b> , 100, 3839-40; author reply 3840-2	2.2	22
2105	188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. <b>2002</b> , 43, 2125-31		60

2104	Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. <b>2002</b> , 20, 3254-61		258
2103	Minimal residual disease in acute myeloid leukaemia. <b>2002</b> , 15, 119-35		20
2102	The significance of minimal residual disease in patients with t(15;17). <b>2002</b> , 15, 137-58		29
2101	De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). <b>2002</b> , 68, 203-9		36
2100	Acute myeloid leukaemia: optimising treatment in elderly patients. <b>2002</b> , 19, 571-81		11
2099	The search for optimal treatment in relapsed and refractory acute myeloid leukemia. <b>2002</b> , 43, 281-91		27
2098	Tryptase a novel biochemical marker of acute myeloid leukemia. <b>2002</b> , 43, 2257-61		39
2097	Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. <i>Blood</i> , <b>2002</b> , 99, 3129-35	2.2	192
2096	Semi-solid colony growth in acute myeloid leukemia and its relation to cytogenetic risk groups. <b>2002</b> , 43, 1743-7		5
2095	Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults. <b>2002</b> , 2, 79-92		23
2094	Minimal residual disease evaluation in acute myeloid leukaemia. <b>2002</b> , 360, 160-2		59
2093	Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. <b>2002</b> , 8, 435-43		26
2092	Treatment of acute myeloid leukemia: state-of-the-art and future directions. <b>2002</b> , 39, 4-10		24
2091	Acute myelogenous leukemia. <b>2002</b> , 32, 50-8		12
2090	Multiplex fluorescent RT-PCR to quantify leukemic fusion transcripts. <b>2002</b> , 33, 158-60, 162, 164		13
2089	The difficult problem of acute myeloid leukemia in the older adult. <b>2002</b> , 52, 363-71		80
2088	Translocation (15;17) and trisomy 21 in the microgranular variant of acute promyelocytic leukemia. <b>2002</b> , 132, 74-6		7
2087	t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia. <b>2002</b> , 132, 133-5		15

2086	Identification of ins(8;21) with AML1/ETO fusion in acute myelogenous leukemia M2 by molecular cytogenetics. <b>2002</b> , 133, 83-6	9
2085	A new nonrandom unbalanced t(17;20) in myeloid malignancies. <b>2002</b> , 138, 32-7	14
2084	Cytogenetic analysis in 139 Tunisian patients with de novo acute myeloid leukemia. <b>2002</b> , 45, 29-32	12
2083	Relationship between chromosomal changes complexity and disease aggressiveness in myeloid and lymphoid disorders. <b>2002</b> , 6, 389-98	1
2082	Focus on acute leukemias. <b>2002</b> , 1, 417-20	138
2081	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. <b>2002</b> , 68, 54-63	15
2080	Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. <b>2002</b> , 68, 345-53	18
2079	Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. <b>2002</b> , 6, 72-85; discussion 86-7	9
2078	Acute myeloid leukemia: treatment of adults under 60 years. <b>2002</b> , 6, 26-45; discussion 86-7	30
2077	Acute myeloid leukemia with inv(16)(p13q22): involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign. <b>2002</b> , 71, 15-9	14
2076	Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. <b>2002</b> , 94, 3292-8	60
2075	Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. <b>2002</b> , 34, 137-53	76
2074	Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. <b>2002</b> , 34, 24-32	51
2073	Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. <b>2002</b> , 33, 395-400	127
2072	Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. <b>2002</b> , 33, 401-12	52
2071	Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. <b>2002</b> , 33, 413-23	40
2070	11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. <b>2002</b> , 33, 362-78	126
2069	Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. <b>2002</b> , 35, 20-9	92

2068	Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. <b>2002</b> , 35, 261-70	14
2067	Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. <b>2002</b> , 33, 60-72	88
2066	MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil. <b>2002</b> , 75, 178-81	5
2065	Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia. <b>2002</b> , 76, 436-45	5
2064	Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. <b>2002</b> , 76 Suppl 2, 65-74	9
2063	Cytogenetics in acute myeloid leukemia. <b>2002</b> , 4, 390-7	43
2062	Older adults with acute myeloid leukemia. <b>2002</b> , 4, 403-9	8
2061	[Pathogenesis and biology of leukemias]. <b>2002</b> , 43, 1179-89	0
2060	Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. <b>2002</b> , 116, 587-94	20
2059	Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase II study. <b>2002</b> , 116, 308-315	4
2058	Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's view. <b>2002</b> , 118, 351-6	35
2057	Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view. <b>2002</b> , 118, 357-64	44
2056	The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. <b>2002</b> , 118, 385-400	258
2055	Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. <b>2002</b> , 119, 1115-24	79
2054	Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK. <b>2002</b> , 24, 263-5	5
2053	Cytoghtique conventionnelle et molculaire des leuchmies aiguës. <b>2002</b> , 2002, 31-40	
2052	Runx1/AML1 in leukemia: disrupted association with diverse protein partners. <b>2002</b> , 26, 221-8	42
2051	High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21). <b>2002</b> , 26, 539-43	15



2050	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. <b>2002</b> , 26, 725-30	38
2049	Antigen expression patterns reflecting genotype of acute leukemias. <b>2002</b> , 16, 1233-58	127
2048	Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. <b>2002</b> , 16, 1381-9	95
2047	Large deletions 5' to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia. <b>2002</b> , 16, 1752-4	19
2046	Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. <b>2002</b> , 16, 1745-51	29
2045	Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. <b>2002</b> , 16, 2072-7	63
2044	Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. <b>2002</b> , 16, 2084-91	61
2043	Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. <b>2002</b> , 16, 1959-73	148
2042	Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. <b>2002</b> , 16, 2177-84	45
2041	Dysregulation of apoptosis genes in hematopoietic malignancies. <b>2002</b> , 21, 3459-74	134
2040	Complex regulation of acetylcholinesterase gene expression in human brain tumors. <b>2002</b> , 21, 8428-41	73
2039	The patient's perspective: a qualitative study of acute myeloid leukaemia patients' need for information and their information-seeking behaviour. <b>2003</b> , 11, 162-70	87
2038	Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. <b>2003</b> , 11, 249-57	67
2037	Relation of in vitro growth characteristics to cytogenetics and treatment outcome in acute myeloid leukemia: prognostic significance in patients with a normal karyotype. <b>2003</b> , 78, 241-7	2
2036	Treatment concepts for elderly patients with acute myeloid leukemia. <b>2003</b> , 115, 505-14	5
2035	Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. <b>2003</b> , 115, 537-46	12
2034	Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. <b>2003</b> , 5, 489-97	12
2033	Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia. <b>2003</b> , 5, 399-404	11

2032	Monitoring of acute myeloid leukemia by flow cytometry. <b>2003</b> , 5, 405-12	16
2031	FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. <b>2003</b> , 82, 231-5	80
2030	Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation. <b>2003</b> , 4, 4	4
2029	Derivative (7)t(7;8)(q34;q21). a new additional cytogenetic abnormality in acute promyelocytic leukemia. <b>2003</b> , 140, 78-81	8
2028	Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. <b>2003</b> , 140, 170-3	9
2027	Double trisomy 8 and 21 in acute myelocytic leukemias, one with rearrangement of the RUNX1 gene. <b>2003</b> , 142, 158-61	
2026	Rearrangement of the MLL gene and a region proximal to the RARalpha gene in a case of acute myelocytic leukemia M5 with a t(11;17)(q23;q21). <b>2003</b> , 145, 54-9	11
2025	Hypocellular acute promyelocytic leukemia with a tetraploid clone characterized by two t(15;17). <b>2003</b> , 145, 169-71	8
2024	Determination of cutoff values to detect small aneuploid clones by interphase fluorescence in situ hybridization: the Poisson model is a more appropriate approach. Should single-cell trisomy 8 be considered a clonal defect?. <b>2003</b> , 147, 99-109	10
2023	Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions. <b>2003</b> , 36, 261-72	29
2022	Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. <b>2003</b> , 37, 149-58	125
2021	Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. <b>2003</b> , 97, 592-600	25
2020	Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. <b>2003</b> , 97, 1481-7	64
2019	Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. <b>2003</b> , 97, 1721-31	35
2018	Immunophenotyping is an independent factor for risk stratification in AML. <b>2003</b> , 53, 11-9	30
2017	Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature. <b>2003</b> , 72, 20-6	15
2016	Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. <b>2003</b> , 27, 205-14	17
2015	Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. <b>2003</b> , 27, 235-42	54

2014	Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. <b>2003</b> , 27, 313-21	32
2013	A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. <b>2003</b> , 27, 529-37	
2012	Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. <b>2003</b> , 27, 1063-6	34
2011	Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. <b>2003</b> , 27, 983-91	19
2010	Molecular evidence for transferrin receptor 2 expression in all FAB subtypes of acute myeloid leukemia. <b>2003</b> , 27, 1101-3	22
2009	The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. <b>2003</b> , 17, 71-97	138
2008	The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. <b>2003</b> , 45, 129-50	60
2007	Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. <b>2003</b> , 120, 56-62	34
2006	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <b>2003</b> , 120, 281-8	80
2005	Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. <b>2003</b> , 120, 434-41	76
2004	Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. <b>2003</b> , 120, 1009-16	22
2003	A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. <b>2003</b> , 120, 960-9	58
2002	Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. <b>2003</b> , 121, 566-77	54
2001	Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxidase in acute myeloid leukaemia: interests of a new positivity threshold. <b>2003</b> , 122, 211-6	16
2000	Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. <b>2003</b> , 122, 217-25	97
1999	Flt3 mutations and leukaemia. <b>2003</b> , 122, 523-38	106
1998	Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. <b>2003</b> , 123, 49-59	64
1997	Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. <b>2003</b> , 123, 219-34	27

1996	Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. <b>2003</b> , 123, 72-80	10
1995	Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. <b>2003</b> , 123, 646-53	15
1994	Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses. <b>2003</b> , 123, 819-29	5
1993	A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement. <b>2003</b> , 25, 255-7	2
1992	Autologous stem cell transplantation for acute myeloid leukemia. <b>2003</b> , 31, 731-8	31
1991	Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. <b>2003</b> , 32, 273-8	3
1990	Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?. <b>2003</b> , 32, 157-64	7
1989	Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. <b>2003</b> , 32, 257-64	16
1988	Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. <b>2003</b> , 32, 889-95	5
1987	Myeloablative conditioning regimens for AML allografts: 30 years later. <b>2003</b> , 32, 969-78	32
1986	More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML. <b>2003</b> , 32, 1119-24	2
1985	A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. <b>2003</b> , 17, 277-82	346
1984	High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. <b>2003</b> , 17, 68-75	58
1983	The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. <b>2003</b> , 17, 60-7	55
1982	Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings. <b>2003</b> , 17, 876-82	23
1981	Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. <b>2003</b> , 17, 1078-84	8
1980	Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. <b>2003</b> , 17, 1130-6	74
1979	Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. <b>2003</b> , 17, 1521-8	102

1978	The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. <b>2003</b> , 17, 1538-43	36
1977	Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. <b>2003</b> , 17, 2244-7	52
1976	Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. <b>2003</b> , 17, 2090-6	67
1975	Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. <b>2003</b> , 17, 2318-57	1188
1974	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. <b>2003</b> , 9, 1158-65	440
1973	Disruption of differentiation in human cancer: AML shows the way. <b>2003</b> , 3, 89-101	502
1972	The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. <b>2003</b> , 27, 387-92	19
1971	Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. <b>2003</b> , 27, 869-70	6
1970	Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes. <b>2003</b> , 17, 1129-49	15
1969	The epidemiology of acute promyelocytic leukaemia. <b>2003</b> , 16, 357-67	51
1968	Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. <b>2003</b> , 38, 274-80	23
1967	Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. <b>2003</b> , 44, 905-13	40
1966	[The interest of standard and molecular cytogenetics for diagnosis of acute leukemia]. <b>2003</b> , 51, 337-45	1
1965	[Chromosomal abnormalities in acute myeloid leukaemias]. <b>2003</b> , 51, 314-28	5
1964	Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations. <b>2003</b> , 34, 352-8	9
1963	Genetic and molecular genetic studies in the diagnosis of myeloid diseases. <b>2003</b> , 34, 306-13	1
1962	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <b>2003</b> , 21, 4642-9	2107
1961	Classification of acute leukemias. <b>2003</b> , 20, 142-53	32

1960	Molecular biology of leukemia. <b>2003</b> , 19, 83-9		1
1959	Grupos de riesgo citogenético en la leucemia mieloide aguda: comparación de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology Group, de EE.UU.). <b>2003</b> , 121, 121-125		
1958	Cytogenetic studies using FISH: background. <b>2003</b> , 220, 173-91		3
1957	Epidemiology and clinical burden of acute myeloid leukemia. <b>2003</b> , 3, 695-710		23
1956	A pulmonary syndrome in patients with acute myelomonocytic leukemia and inversion of chromosome 16. <b>2003</b> , 44, 103-9		10
1955	Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre. <b>2003</b> , 44, 1441-3		6
1954	Identification of a gene expression signature associated with pediatric AML prognosis. <i>Blood</i> , <b>2003</b> , 102, 1849-56	2.2	151
1953	Multicolor karyotyping in acute myeloid leukemia. <b>2003</b> , 44, 1843-53		16
1952	Pediatric acute lymphoblastic leukemia. <b>2003</b> , 2003, 102-31		92
1951	Dysplasia and High Proliferation Rate Are Common in Acute Myeloid Leukemia With inv(16)(p13q22). <b>2003</b> , 120, 236-245		15
1950	Prognostic Impact of Acute Myeloid Leukemia Classification. <b>2003</b> , 119, 672-680		90
1949	Screening and quantification of multiple chromosome translocations in human leukemia. <b>2003</b> , 49, 1066-73		11
1948	Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. <b>2003</b> , 23, 9375-88		109
1947	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia. <b>2003</b> , 119, 663-671		32
1946	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients. <b>2003</b> , 14, 1161-2		2
1945	6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients with acute myeloid leukemia (AML): a randomized trial. <b>2003</b> , 119, 663-671		135
1944	Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. <b>2003</b> , 21, 1722-7		73
1943	Cancer Cytogenetics. <b>2003</b> ,		10

1942	Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. <b>2003</b> , 21, 4413-22		108
1941	Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations. <b>2003</b> , 2, 201-209		122
1940	Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. <i>Blood</i> , <b>2003</b> , 101, 64-70	2.2	221
1939	Tumor Suppressor Genes. <b>2003</b> ,		1
1938	Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. <i>Blood</i> , <b>2003</b> , 102, 462-9	2.2	152
1937	Clinical Significance of Cytogenetics in Acute Leukemias. <b>2003</b> , 34, 796-802		1
1936	Highly complex karyotypic changes in acute myelogenous leukemia: a case report. <b>2003</b> , 23, 139		
1935	Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. <b>2003</b> , 119, 672-80		27
1934	Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). <b>2003</b> , 120, 236-45		6
1933	Characterization of translocations in human cancer. <b>2003</b> , 222, 327-37		
1932	The myeloid disorders: background. <b>2003</b> , 220, 23-42		1
1931	Recent advances in pediatric acute lymphoblastic and myeloid leukemia. <b>2003</b> , 15, 23-35		63
1930	Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. <b>2003</b> , 8, 83-90		3
1929	Acute promyelocytic leukemia: a case-based review. <b>2003</b> , 8, 105-13		2
1928	Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. <b>2003</b> , 25, 696-703		38
1927	Metaphase harvest and cytogenetic analysis of malignant hematological specimens. <b>2003</b> , Chapter 10, Unit 10.2		3
1926	CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. <i>Blood</i> , <b>2003</b> , 101, 2770-4	2.2	36
1925	Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. <i>Blood</i> , <b>2003</b> , 101, 289-91	2.2	61



1924	The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. <i>Blood</i> , <b>2003</b> , 101, 624-32	2.2	44
1923	Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. <i>Blood</i> , <b>2003</b> , 101, 3398-406	2.2	165
1922	FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. <i>Blood</i> , <b>2003</b> , 102, 2387-94	2.2	181
1921	Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. <i>Blood</i> , <b>2003</b> , 102, 1232-40	2.2	288
1920	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. <i>Blood</i> , <b>2003</b> , 102, 1613-8	2.2	202
1919	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. <i>Blood</i> , <b>2003</b> , 102, 4290-7	2.2	147
1918	A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. <i>Blood</i> , <b>2003</b> , 102, 4277-83	2.2	160
1917	AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. <i>Blood</i> , <b>2003</b> , 102, 2395-402	2.2	258
1916	Leukemia, myelodysplastic syndrome and myeloproliferative disorder. <b>2003</b> , 317-330		
1915	[Karyotype in acute myeloid leukemia: importance and type of aberrations in 30 patients at diagnosis]. <b>2003</b> , 49, 150-5		6
1914	Acute myeloid leukemia in elderly patients: experience of a single center. <b>2003</b> , 36, 703-8		11
1913	Management of acute myelogenous leukemia in the elderly. <b>2003</b> , 10, 469-77		18
1912	Use of fludarabine in the treatment of acute myeloid leukemia. <b>2004</b> , 5 Suppl 1, S62-7		14
1911	Bone marrow microvessel density and its prognostic significance in AML. <b>2004</b> , 45, 1369-73		26
1910	Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. <b>2004</b> , 22, 1276-86		57
1909	FISHing [Current Status and Future Prospects for Improved Management of Leukemia. <b>2004</b> , 02, 131-141		
1908	Large-scale identification of disease genes involved in acute myeloid leukemia. <b>2004</b> , 78, 1971-80		38
1907	Gene expression profiling of pediatric acute myelogenous leukemia. <i>Blood</i> , <b>2004</b> , 104, 3679-87	2.2	357



1906	FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. <b>2004</b> , 112, 68-78	61
1905	Granulocytic sarcoma of the colon and leukemic infiltration of the liver in a patient presenting with hematochezia and jaundice. <b>2004</b> , 69, 262-5	21
1904	No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?. <b>2004</b> , 45, 1361-4	3
1903	Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. <b>2004</b> , 121, 45-67	11
1902	Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. <b>2004</b> , 279, 31991-4	138
1901	Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. <b>2004</b> , 22, 1087-94	166
1900	Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. <b>2004</b> , 22, 2410-8	89
1899	Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. <b>2004</b> , 22, 582-4	13
1898	Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. <b>2004</b> , 22, 3741-50	260
1897	Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. <b>2004</b> , 10, 7896-902	158
1896	Cytogenetic abnormalities in de novo acute myeloid leukemia in adults: relation to morphology, age, sex and ethnicity - a single center study from Singapore. <b>2004</b> , 5, 419-25	16
1895	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs. <b>2004</b> , 50, 1165-73	9
1894	Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. <b>2004</b> , 125, 42-9	27
1893	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. <b>2004</b> , 125, 203-12	22
1892	A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. <b>2004</b> , 125, 477-9	19
1891	WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. <b>2004</b> , 125, 590-600	155
1890	Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. <b>2004</b> , 126, 320-37	26
1889	Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients. <b>2004</b> , 127, 59-66	31

1888	Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. <b>2004</b> , 127, 264-79	25
1887	Human leukaemic stem cells: a novel target of therapy. <b>2004</b> , 34 Suppl 2, 31-40	24
1886	Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. <b>2004</b> , 33, 1201-8	12
1885	Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. <b>2004</b> , 18, 120-5	222
1884	High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy. <b>2004</b> , 18, 303-8	4
1883	Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. <b>2004</b> , 18, 293-302	49
1882	Incidence and prognostic value of respiratory events in acute leukemia. <b>2004</b> , 18, 670-5	81
1881	Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. <b>2004</b> , 18, 420-5	61
1880	Erythroleukaemia and RAEB-t: a same disease?. <b>2004</b> , 18, 888-90	13
1879	Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. <b>2004</b> , 18, 939-47	57
1878	Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. <b>2004</b> , 18, 1059-63	50
1877	MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. <b>2004</b> , 18, 1380-90	142
1876	Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. <b>2004</b> , 18, 1427-9	7
1875	A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia. <b>2004</b> , 18, 1522-30	24
1874	The role of allogeneic transplantation in high-risk acute myelogenous leukemia. <b>2004</b> , 18, 1565-8	16
1873	Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. <b>2004</b> , 18, 1804-9	21
1872	PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. <b>2004</b> , 18, 1831-4	101
1871	Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. <b>2004</b> , 23, 2379-84	51

1870	Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. <b>2004</b> , 23, 9381-91	41
1869	Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). <b>2004</b> , 17, 1211-6	14
1868	Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. <b>2004</b> , 72, 307-13	46
1867	Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. <b>2004</b> , 72, 38-44	6
1866	Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults. <b>2004</b> , 31, 80-6	13
1865	Cytoprotection in acute myelogenous leukemia (AML) therapy. <b>2004</b> , 31, 67-73	14
1864	Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. <b>2004</b> , 148, 29-34	31
1863	Inversion of chromosome 12 and lineage promiscuity in hematologic malignancies. <b>2004</b> , 148, 91-103	1
1862	Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. <b>2004</b> , 148, 176-7	6
1861	A novel t(6;14)(q25-q27;q32) in acute myelocytic leukemia involves the BCL11B gene. <b>2004</b> , 149, 72-6	28
1860	Heterogeneity of structural abnormalities in the 7q31.3 approximately q34 region in myeloid malignancies. <b>2004</b> , 150, 136-43	11
1859	Occurrence of a variant Philadelphia translocation, t(10;22), in de novo acute megakaryoblastic leukemia. <b>2004</b> , 152, 52-5	2
1858	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <b>2004</b> , 151, 85-6	0
1857	Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. <b>2004</b> , 152, 29-41	35
1856	Derivative (7)t(7;8)(q34;q21): an additional chromosome aberration in acute promyelocytic leukemia-prognostic influence debated. <b>2004</b> , 153, 81-3	3
1855	Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. <b>2004</b> , 153, 16-25	26
1854	Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping. <b>2004</b> , 153, 39-47	24
1853	Deletion of CFBF in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16. <b>2004</b> , 154, 60-2	13

1852	Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. <b>2004</b> , 155, 47-56	32
1851	Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. <b>2004</b> , 79, 495-500	15
1850	Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies. <b>2004</b> , 80, 120-7	8
1849	Stratification of acute myeloid leukemia based on gene expression profiles. <b>2004</b> , 80, 389-94	9
1848	Acute myeloid leukemia. <b>2004</b> , 2004, 98-117	164
1847	Adult acute myeloid leukaemia. <b>2004</b> , 50, 197-222	126
1846	A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. <b>2004</b> , 83, 78-83	22
1845	Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience. <b>2004</b> , 83, 218-24	10
1844	Pharmacodynamic pitfalls in antifungal treatment. <b>2004</b> , 83 Suppl 1, S40	2
1843	Modern diagnostics in chronic myeloproliferative diseases (CMPDs). <b>2004</b> , 83 Suppl 1, S59-61	17
1842	Risk-adapted induction and consolidation therapy in adults with de novo AML aged . <b>2004</b> , 83, 336-44	49
1841	Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. <b>2004</b> , 83, 696-703	25
1840	Highly refractory acute myeloid leukemia. <b>2004</b> , 116, 561-4	2
1839	Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. <b>2004</b> , 28, 43-8	93
1838	The therapy of relapsed acute leukaemia in adults. <b>2004</b> , 18, 39-63	12
1837	Cytogenetics in acute leukemia. <b>2004</b> , 18, 115-36	506
1836	Childhood acute myeloid leukemia with CBFbeta-MYH11 rearrangement: study of incidence, morphology, cytogenetics, and clinical outcomes of Chinese in Hong Kong. <b>2004</b> , 76, 300-3	8
1835	Cryptic insertion of MLL gene into 9p22 leads to MLL-MLLT3 (AF9) fusion in a case of acute myelogenous leukemia. <b>2004</b> , 40, 349-54	10

1834	A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia. <b>2004</b> , 41, 272-7	12
1833	Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. <b>2004</b> , 101, 1420-7	30
1832	Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. <b>2004</b> , 28, 359-65	35
1831	Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. <b>2004</b> , 45, 1803-8	24
1830	Evolution of clonal cytogenetic abnormalities in aplastic anemia. <b>2004</b> , 45, 433-40	63
1829	CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. <b>2004</b> , 22, 624-33	379
1828	Dose dependent long-term in vivo remission of AML1/ETO positive acute myeloid leukemia with G-CSF. <b>2004</b> , 9, 107-11	3
1827	Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study. <b>2004</b> , 45, 971-7	4
1826	Rapid Cycle Real-Time PCR [Methods and Applications. <b>2004</b> ,	3
1825	Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. <b>2004</b> , 350, 1605-16	822
1824	Prognostically useful gene-expression profiles in acute myeloid leukemia. <b>2004</b> , 350, 1617-28	1106
1823	Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis. <b>2004</b> , 6, 22-7	11
1822	Understanding cancer at the chromosome level: 40 years of progress. <b>2004</b> , 40, 1960-7	6
1821	Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia. <b>2004</b> , 33, 294-302	14
1820	MLL: a histone methyltransferase disrupted in leukemia. <b>2004</b> , 10, 500-7	278
1819	Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. <b>2004</b> , 35, 246-53	64
1818	Unanswered questions in acute myeloid leukaemia. <b>2004</b> , 5, 443-50	59
1817	Molecular cytogenetic studies for hematological malignancies. <b>2004</b> , 121, 69-112	7

1816	Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by fluorescent in situ hybridization. <b>2004</b> , 26, 431-4		10
1815	Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. <i>Blood</i> , <b>2004</b> , 104, 3872-7	2.2	98
1814	A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. <i>Blood</i> , <b>2004</b> , 103, 479-85	2.2	238
1813	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , <b>2004</b> , 103, 698-700	2.2	75
1812	Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. <i>Blood</i> , <b>2004</b> , 104, 550-7	2.2	233
1811	Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. <i>Blood</i> , <b>2004</b> , 104, 3078-85	2.2	220
1810	CXCR-4: homing in on Flt3. <i>Blood</i> , <b>2004</b> , 104, 303-304	2.2	
1809	Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. <b>2005</b> , 12, 68-75		95
1808	Gene expression profiling in acute myeloid leukemia. <b>2005</b> , 12, 76-81		31
1807	Acute promyelocytic leukemia: a model of molecular target based therapy. <b>2005</b> , 10 Suppl 1, 270-80		15
1806	Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. <i>Blood</i> , <b>2005</b> , 105, 3035-41	2.2	36
1805	A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. <i>Blood</i> , <b>2005</b> , 105, 481-8	2.2	78
1804	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , <b>2005</b> , 105, 1810-4	2.2	247
1803	Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. <i>Blood</i> , <b>2005</b> , 106, 494-504	2.2	360
1802	Global approach to the diagnosis of leukemia using gene expression profiling. <i>Blood</i> , <b>2005</b> , 106, 1189-98.2		160
1801	Drug therapy for acute myeloid leukemia. <i>Blood</i> , <b>2005</b> , 106, 1154-63	2.2	521
1800	RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. <i>Blood</i> , <b>2005</b> , 106, 2113-9	2.2	204
1799	No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. <i>Blood</i> , <b>2005</b> , 106, 3658-65	2.2	196

1798	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. <i>Blood</i> , <b>2005</b> , 106, 3740-6	2.2	666
1797	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. <i>Blood</i> , <b>2005</b> , 106, 3618-20	2.2	191
1796	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. <i>Blood</i> , <b>2005</b> , 106, 3733-9	2.2	571
1795	More flitting about FLT3. <i>Blood</i> , <b>2005</b> , 106, 3331-3332	2.2	7
1794	Acquired chromosome abnormalities: the cytogenetics of cancer. <b>2005</b> ,		
1793	BCRP mRNA expression v. clinical outcome in 40 adult AML patients. <b>2005</b> , 29, 141-6		79
1792	Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. <b>2005</b> , 29, 617-23		22
1791	Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients. <b>2005</b> , 29, 1109-16		34
1790	Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. <b>2005</b> , 19, 223-34		39
1789	Modern diagnostics in acute leukemias. <b>2005</b> , 56, 223-34		50
1788	Monitoring of minimal residual disease in acute myeloid leukemia. <b>2005</b> , 56, 283-309		49
1787	Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?. <b>2005</b> , 128, 18-34		62
1786	Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. <b>2005</b> , 128, 42-8		45
1785	High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. <b>2005</b> , 128, 234-41		20
1784	Biology and management of relapsed acute myeloid leukaemia. <b>2005</b> , 129, 18-34		72
1783	MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. <b>2005</b> , 128, 324-32		139
1782	Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. <b>2005</b> , 128, 318-23		24
1781	Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. <b>2005</b> , 128, 783-91		24



1780	Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. <b>2005</b> , 129, 189-98	26
1779	Del (9q) AML: clinical and cytological characteristics and prognostic implications. <b>2005</b> , 129, 210-20	42
1778	Somatic PTPN11 mutations in childhood acute myeloid leukaemia. <b>2005</b> , 129, 333-9	64
1777	Prognosis of patients with acute myeloid leukaemia admitted to intensive care. <b>2005</b> , 129, 350-7	80
1776	Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. <b>2005</b> , 130, 825-33	22
1775	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <b>2005</b> , 131, 172-9	39
1774	Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. <b>2005</b> , 131, 457-67	27
1773	Failed or inadequate bone marrow aspiration: a fast, simple and cost-effective method to produce a cell suspension from a core biopsy specimen. <b>2005</b> , 27, 33-40	12
1772	Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders. <b>2005</b> , 27, 148-71	17
1771	Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). <b>2005</b> , 35, 143-9	24
1770	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. <b>2005</b> , 35, 965-70	48
1769	Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. <b>2005</b> , 35, 1011-8	84
1768	Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. <b>2005</b> , 36, 67-70	17
1767	Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. <b>2005</b> , 36, 183-91	40
1766	FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. <b>2005</b> , 36, 977-83	29
1765	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <b>2005</b> , 19, 317-8	2
1764	CEBPalpha mutations in childhood acute myeloid leukemia. <b>2005</b> , 19, 410-4	42
1763	CEBPA point mutations in hematological malignancies. <b>2005</b> , 19, 329-34	134



1762	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <b>2005</b> , 19, 402-9	72
1761	Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). <b>2005</b> , 19, 367-72	101
1760	Clinical and biological features of favorable-risk acute myelogenous leukemia--is favorable-risk AML really favorable?. <b>2005</b> , 19, 326-8	2
1759	Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. <b>2005</b> , 19, 965-70	42
1758	The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. <b>2005</b> , 19, 916-20	92
1757	Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). <b>2005</b> , 19, 1361-6	90
1756	Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. <b>2005</b> , 19, 1345-9	227
1755	Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. <b>2005</b> , 19, 2043-53	69
1754	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. <b>2005</b> , 19, 1536-42	199
1753	Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. <b>2005</b> , 19, 1760-7	124
1752	Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. <b>2005</b> , 19, 2072-81	62
1751	Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. <b>2005</b> , 19, 2090-100	119
1750	Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. <b>2005</b> , 24, 1580-8	54
1749	Molecular mechanisms of cellular transformation by HTLV-1 Tax. <b>2005</b> , 24, 5976-85	324
1748	Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. <b>2005</b> , 160, 97-119	16
1747	3'CBFbeta deletion associated with inv(16) in acute myeloid leukemia. <b>2005</b> , 162, 122-6	13
1746	Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. <b>2005</b> , 162, 127-34	20
1745	A cryptic three-way translocation involving chromosomes 8, 14, and 21 in a case of acute myeloid leukemia subtype M1. <b>2005</b> , 163, 86-90	3

1744	CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. <b>2005</b> , 163, 62-7	31
1743	Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. <b>2005</b> , 33, 120-30	11
1742	Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. <b>2005</b> , 74, 418-23	31
1741	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. <b>2005</b> , 75, 73-7	3
1740	Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. <b>2005</b> , 75, 185-92	13
1739	Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. <b>2005</b> , 6, 265	146
1738	Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts. <b>2005</b> , 5, 60	2
1737	Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1. <b>2005</b> , 96, 795-809	17
1736	Nonrandom aneuploidy of chromosomes 1, 5, 6, 7, 8, 9, 11, 12, and 21 induced by the benzene metabolites hydroquinone and benzenetriol. <b>2005</b> , 45, 388-96	32
1735	Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. <b>2005</b> , 42, 358-71	42
1734	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. <b>2005</b> , 42, 427-32	33
1733	Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. <b>2005</b> , 42, 287-98	35
1732	Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. <b>2005</b> , 43, 227-38	147
1731	Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-rich regions of the genome. <b>2005</b> , 43, 383-9	28
1730	Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. <b>2005</b> , 44, 279-91	40
1729	When epigenetics kills: MLL fusion proteins in leukemia. <b>2005</b> , 23, 1-9	70
1728	Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. <b>2005</b> , 23, 18-25	29
1727	Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. <b>2005</b> , 103, 393-401	26

1726	Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. <b>2005</b> , 103, 1652-8	141
1725	Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. <b>2005</b> , 103, 2082-90	75
1724	Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. <b>2005</b> , 104, 110-7	109
1723	Outcome of patients with acute myelogenous leukemia after second salvage therapy. <b>2005</b> , 104, 547-54	57
1722	Leukemic transformation of polycythemia vera: a single center study of 23 patients. <b>2005</b> , 104, 1032-6	67
1721	Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. <b>2005</b> , 84, 25-32	16
1720	Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. <b>2005</b> , 84 Suppl 1, 39-46	67
1719	Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia. <b>2005</b> , 84, 368-75	12
1718	Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. <b>2005</b> , 84, 785-91	32
1717	Centrosome aberrations in hematological malignancies. <b>2005</b> , 29, 375-83	49
1716	Detection of AML1/MTG8 fusion gene of spinal granulocytic sarcoma in a nonleukemic patient using the real-time polymerase chain reaction. <b>2005</b> , 10, 414-7	0
1715	Advances in the molecular genetics of acute leukemia. <b>2005</b> , 7, 323-32	3
1714	Cytogenetics of Hematologic Neoplasms. <b>2005</b> , 365-420	1
1713	Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. <b>2005</b> , 23, 9234-42	199
1712	Akute Leukämien. <b>2005</b> , 1099-1107	
1711	FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications. <b>2005</b> , 11, 3449-57	21
1710	DNA topoisomerase II in therapy-related acute promyelocytic leukemia. <b>2005</b> , 352, 1529-38	229
1709	Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. <b>2005</b> , 11, 4793-801	24

1708	High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. <b>2005</b> , 11, 8644-52		59
1707	Risk assessment in patients with acute myeloid leukemia and a normal karyotype. <b>2005</b> , 11, 1416-24		194
1706	ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. <b>2005</b> , 16 Suppl 1, i48-9		5
1705	Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. <b>2005</b> , 23, 482-93		106
1704	Treatment of childhood acute myeloid leukemia. <b>2005</b> , 5, 917-29		6
1703	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia. <b>2005</b> , 352, 274-83		6
1702	Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated. <b>2005</b> , 46, 401-4		1
1701	Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. <b>2005</b> , 46, 525-31		3
1700	Prognostic index for adult patients with acute myeloid leukemia in first relapse. <b>2005</b> , 23, 1969-78		396
1699	The Principles of Clinical Cytogenetics. <b>2005</b> ,		25
1698	Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. <i>Blood</i> , <b>2005</b> , 106, 3768-76	2.2	180
1697	Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. <b>2005</b> , 23, 5675-87		314
1696	Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report. <b>2005</b> , 22, 597-608		2
1695	Gene expression profiling in acute myeloid leukemia. <b>2005</b> , 23, 6296-305		84
1694	Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. <b>2005</b> , 23, 5705-17		272
1693	Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. <b>2005</b> , 114, 78-83		14
1692	Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. <b>2005</b> , 23, 7676-84		53
1691	Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. <b>2005</b> , 11, 5708-17		89

1690	Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. <b>2005</b> , 11, 6536-43		14
1689	Monitoring of minimal residual disease in acute myeloid leukemia Monitorisierung minimaler Resterkrankung bei akuter myeloischer Leukämie. <b>2005</b> , 29, 343-367		
1688	Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. <b>2005</b> , 16, 1366-73		39
1687	FISH-Diagnostik bei hämatologischen Neoplasien FISH diagnostics in hematological malignancies. <b>2005</b> , 29, 335-342		
1686	MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. <b>2005</b> , 11, 7764-72		131
1685	Current issues in pediatric stem cell transplantation. <b>2005</b> , 25, 519-40		9
1684	Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. <i>Blood</i> , <b>2005</b> , 106, 2854-61	2.2	225
1683	CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. <b>2005</b> , 46, 1115-20		24
1682	Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia. <b>2005</b> , 46, 63-70		5
1681	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. <i>Blood</i> , <b>2005</b> , 106, 3747-54	2.2	471
1680	Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. <b>2005</b> , 333, 703-13		31
1679	Genetics of myeloid malignancies: pathogenetic and clinical implications. <b>2005</b> , 23, 6285-95		281
1678	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. <b>2005</b> , 352, 254-66		1374
1677	Atypical myeloproliferative disorders: diagnosis and management. <b>2006</b> , 81, 553-63		38
1676	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. <i>Blood</i> , <b>2006</b> , 107, 880-4	2.2	63
1675	Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. <b>2006</b> , 47, 1245-52		74
1674	Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. <b>2006</b> , 47, 697-706		3
1673	Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients. <b>2006</b> , 47, 2203-7		9

1672	Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. <b>2006</b> , 47, 1788-93	25
1671	Acute myeloid leukaemia. <b>2006</b> , 368, 1894-907	960
1670	Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <b>2006</b> , 24, 444-53	220
1669	Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. <b>2006</b> , 24, 3887-94	127
1668	Adult acute myeloid leukemia. <b>2006</b> , 81, 247-60	90
1667	Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. <b>2006</b> , 19, 571-93	36
1666	How good is allogeneic transplantation for high-risk patients with AML?. <b>2006</b> , 19, 329-32	6
1665	Is there a role for consolidation therapy pre-transplantation?. <b>2006</b> , 19, 301-10	3
1664	Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. <b>2006</b> , 19, 825-38	27
1663	Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. <b>2006</b> , 8, 254-9	31
1662	Detection and monitoring of minimal residual disease by quantitative real-time PCR. <b>2006</b> , 363, 147-56	28
1661	Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. <b>2006</b> , 12, 480-9	14
1660	Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. <b>2006</b> , 12, 1169-75	17
1659	Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. <b>2006</b> , 12, 1310-7	18
1658	Chromatin structural elements and chromosomal translocations in leukemia. <b>2006</b> , 5, 1282-97	138
1657	Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. <b>2006</b> , 211, 677-85	26
1656	Combined spectral karyotyping, comparative genomic hybridization, and in vitro apotyping of a panel of Burkitt's lymphoma-derived B cell lines reveals an unexpected complexity of chromosomal aberrations and a recurrence of specific abnormalities in chemoresistant cell lines. <b>2006</b> , 28, 605	2
1655	Acute myeloid leukemia. 499-539	2

1654	Diagnosis and classification. 21-47		5
1653	Stem Cells in Neurodegeneration and Injury. <b>2006</b> , 287-320		
1652	Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. <i>Blood</i> , <b>2006</b> , 107, 3463-8	2.2	295
1651	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. <i>Blood</i> , <b>2006</b> , 107, 4514-23	2.2	201
1650	KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. <i>Blood</i> , <b>2006</b> , 107, 1791-9	2.2	319
1649	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , <b>2006</b> , 107, 2184-91	2.2	132
1648	AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. <i>Blood</i> , <b>2006</b> , 107, 1166-73	2.2	192
1647	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. <i>Blood</i> , <b>2006</b> , 108, 45-51	2.2	132
1646	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. <i>Blood</i> , <b>2006</b> , 108, 88-96	2.2	183
1645	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , <b>2006</b> , 108, 63-73	2.2	253
1644	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , <b>2006</b> , 108, 1999-2005	2.2	146
1643	Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. <i>Blood</i> , <b>2006</b> , 108, 3530-7	2.2	50
1642	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. <i>Blood</i> , <b>2006</b> , 108, 3280-8	2.2	234
1641	Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. <i>Blood</i> , <b>2006</b> , 108, 3843-50	2.2	41
1640	Older AML patients: fit for what?. <i>Blood</i> , <b>2006</b> , 108, 3232-3233	2.2	7
1639	Pronostic et traitement des leucmies aiguës myéloblastiques. <b>2006</b> , 1, 1-13		
1638	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. <b>2006</b> , 47, 931-5		41
1637	Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. <b>2006</b> , 6 Suppl 1, S293-9		53



1636	Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. <b>2006</b> , 132, 576-83	81
1635	Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. <b>2006</b> , 134, 58-60	21
1634	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. <b>2006</b> , 135, 165-73	196
1633	Guidelines on the management of acute myeloid leukaemia in adults. <b>2006</b> , 135, 450-74	109
1632	t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. <b>2006</b> , 135, 673-82	19
1631	Translocation between chromosome 5q35 and chromosome 11q13-- an unusual cytogenetic finding in a primary refractory acute myeloid leukemia. <b>2006</b> , 28, 160-3	4
1630	Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. <b>2006</b> , 20, 87-94	125
1629	Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia. <b>2006</b> , 20, 48-54	31
1628	Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. <b>2006</b> , 20, 218-23	96
1627	Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia. <b>2006</b> , 20, 247-53	9
1626	Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia. <b>2006</b> , 20, 444-50	34
1625	AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. <b>2006</b> , 20, 604-9	41
1624	Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. <b>2006</b> , 20, 707-14	49
1623	High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. <b>2006</b> , 20, 840-6	70
1622	Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. <b>2006</b> , 20, 1706-16	73
1621	The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. <b>2006</b> , 20, 1883-5	2
1620	Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. <b>2006</b> , 20, 1943-9	125
1619	DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. <b>2006</b> , 20, 2130-6	65



1618	Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. <b>2006</b> , 25, 7041-58	43
1617	The fundamental role of epigenetics in hematopoietic malignancies. <b>2006</b> , 20, 1-13	174
1616	Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. <b>2006</b> , 30, 190-203	34
1615	Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. <b>2006</b> , 30, 389-95	51
1614	Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. <b>2006</b> , 30, 503-6	12
1613	Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia. <b>2006</b> , 30, 1105-12	7
1612	Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. <b>2006</b> , 30, 943-8	10
1611	Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22). <b>2006</b> , 84, 417-20	1
1610	Intensifying daunorubicin in induction for patients with core binding factor leukemia. <b>2006</b> , 84, 463-4	2
1609	A role for mitotic recombination in leukemogenesis. <b>2006</b> , 46, 90-7	13
1608	A novel chromosomal abnormality involving 2q37 in myeloid malignancies. <b>2006</b> , 85, 333-4	
1607	Satellite Symposia and Meet-the-Professor Sessions. <b>2006</b> , 85, 28-126	2
1606	Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. <b>2006</b> , 85, 357-65	5
1605	[Optimized RT-PCR based detection of specific genetic abnormalities within malignant hematopoietic disorders]. <b>2006</b> , 27, 182-7	1
1604	Molecular biology in acute leukemia. <b>2006</b> , 8, 550-9	5
1603	Chemotherapy for patients with acute myeloid leukemia in first remission. <b>2006</b> , 1, 108-13	4
1602	Clinical implications of gene expression profiling of acute myeloid leukemia. <b>2006</b> , 1, 114-21	1
1601	Chromosome 21 abnormalities: a review and report of a case of Erondy-Cymet syndrome. <b>2006</b> , 32, 254-60	

1600	Multipoint interphase FISH analysis of chromosome 3 abnormalities in 28 childhood AML patients. <b>2006</b> , 76, 124-33	8
1599	Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. <b>2006</b> , 77, 35-45	32
1598	del(6)(p23) in two cases of de novo AML--a new recurrent primary chromosome abnormality. <b>2006</b> , 77, 245-50	3
1597	Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. <b>2006</b> , 34, 1360-76	27
1596	Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR). <b>2006</b> , 165, 1-8	6
1595	Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. <b>2006</b> , 165, 51-63	25
1594	Translocation (4;9)(q11;q33), a new rearrangement in acute myeloid leukemia with central nervous system involvement. <b>2006</b> , 165, 85-6	1
1593	Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. <b>2006</b> , 7, 198	21
1592	High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. <b>2006</b> , 107, 116-24	79
1591	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. <b>2006</b> , 106, 112-9	197
1590	Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. <b>2006</b> , 106, 839-47	31
1589	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. <b>2006</b> , 106, 1090-8	478
1588	Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. <b>2006</b> , 106, 2495-502	47
1587	Acute myeloid leukemia: epidemiology and etiology. <b>2006</b> , 107, 2099-107	420
1586	Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. <b>2006</b> , 118, 2195-201	68
1585	Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics. <b>2006</b> , 73, 271-9	4
1584	Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. <b>2006</b> , 2006, 169-77	91
1583	Cloretazine for the treatment of acute myeloid leukemia. <b>2006</b> , 6, 321-8	7

1582	Abstracts from the Chemotherapy Foundation Symposium XXIV: Innovative Cancer Therapy for Tomorrow, November 8-11, 2006, New York, New York, USA. <b>2006</b> , 24 Suppl 1, 1-59		
1581	Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. <b>2006</b> , 7, 199-207		15
1580	Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. <b>2006</b> , 7, 185-98		2
1579	High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. <b>2006</b> , 24, 1507-15		141
1578	Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. <b>2006</b> , 12, 1284-91		37
1577	Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions. <b>2006</b> , 12, 3564s-71s		9
1576	Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. <b>2006</b> , 24, e23-5		16
1575	Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. <i>Blood</i> , <b>2006</b> , 107, 4871-9	2.2	58
1574	Pediatric Hematopoietic Stem Cell Transplantation. <b>2006</b> ,		1
1573	Tissue Stem Cells. <b>2006</b> ,		3
1572	Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. <b>2006</b> , 66, 3310-6		150
1571	Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures. <b>2006</b> , 116, 77-89		21
1570	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. <b>2006</b> , 24, 3904-11		534
1569	Perspectives of proteomics in acute myeloid leukemia. <b>2006</b> , 6, 1663-75		9
1568	Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. <b>2006</b> , 12, 7018-24		20
1567	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. <b>2006</b> , 20, 1913-5		47
1566	Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. <b>2006</b> , 66, 6947-54		111
1565	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. <b>2007</b> , 92, 519-32		156

1564	Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. <b>2007</b> , 18, 529-34		7
1563	CYP1A1 polymorphisms modify overall survival in acute myeloid leukemia patients. <b>2007</b> , 48, 1211-5		5
1562	Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. <b>2007</b> , 127, 197-205		73
1561	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. <i>Blood</i> , <b>2007</b> , 109, 3189-97	2.2	564
1560	MRC trials in acute myeloblastic leukemia: where have we got to?. <b>2007</b> , 48, 2289-90		4
1559	Drug resistance in childhood acute myeloid leukemia. <b>2007</b> , 8, 59-75		17
1558	Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. <b>2007</b> , 2007, 392-7		59
1557	Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. <b>2007</b> , 12, 393-401		15
1556	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. <b>2007</b> , 48, 1187-99		13
1555	Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients. <b>2007</b> , 48, 1654-8		17
1554	LEUKEMIA STEM CELLS: STUDYING THE ROOT OF LEUKEMIA. <b>2007</b> , 03, 65-90		
1553	Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. <b>2007</b> , 25, 1209-15		41
1552	Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. <b>2007</b> , 25, 25-31		64
1551	Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. <b>2007</b> , 128, 550-7		22
1550	Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. <b>2007</b> , 25, 4262-9		52
1549	Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. <b>2007</b> , 12, 341-55		79
1548	Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. <b>2007</b> , 127, 642-50		143
1547	Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2007</b> , 18 Suppl 2, ii47-8		8

1546	Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. <b>2007</b> , 13, 7059-66		36
1545	Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. <b>2007</b> , 13, 4777-85		81
1544	Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. <b>2007</b> , 117, 109-14		5
1543	Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. <b>2007</b> , 13, 5048-55		103
1542	Early gene expression of acute myeloid leukemia in response to chemotherapy. <b>2007</b> , 7, 741-51		2
1541	An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia. <b>2007</b> , 46, 325-7		10
1540	Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. <b>2007</b> , 46, 1011-4		14
1539	Recent developments in acute myelogenous leukemia therapy. <b>2007</b> , 12 Suppl 2, 14-21		17
1538	Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. <b>2007</b> , 92, e85-90		20
1537	Acute Myeloid Leukemias. 367-424		5
1536	Gene expression profile related to prognosis of acute myeloid leukemia. <b>2007</b> ,		2
1535	Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. <i>Blood</i> , <b>2007</b> , 109, 3441-50	2.2	161
1534	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. <i>Blood</i> , <b>2007</b> , 109, 4641-7	2.2	112
1533	CXCR4 is a prognostic marker in acute myelogenous leukemia. <i>Blood</i> , <b>2007</b> , 109, 786-91	2.2	252
1532	A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. <i>Blood</i> , <b>2007</b> , 109, 1233-6	2.2	21
1531	Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. <i>Blood</i> , <b>2007</b> , 110, 409-17	2.2	64
1530	Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. <i>Blood</i> , <b>2007</b> , 110, 1291-300	2.2	100
1529	The incidence and clinical significance of nucleophosmin mutations in childhood AML. <i>Blood</i> , <b>2007</b> , 110, 979-85	2.2	166

1528	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. <i>Blood</i> , <b>2007</b> , 110, 4385-95	2.2	585
1527	Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , <b>2007</b> , 110, 4606-13	2.2	262
1526	Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. <i>Blood</i> , <b>2007</b> , 110, 4172-4	2.2	57
1525	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <b>2007</b> , 92, 763-70		39
1524	Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. <b>2007</b> , 14, 130-7		15
1523	Molecular characterization of acute myeloid leukemia and its impact on treatment. <b>2007</b> , 19, 635-49		20
1522	Alternative donor transplantation in acute myeloid leukemia: which source and when?. <b>2007</b> , 14, 152-61		18
1521	Advances in Molecular Cytogenetics to Study the Leukemia Genome. <b>2007</b> , 38, 527-535		1
1520	Anomalies chromosomiques et gñiques dans les hñmopathies malignes. <b>2007</b> , 2, 1-13		
1519	Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. <b>2007</b> , 55, 37-48		71
1518	A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. <b>2007</b> , 13, 560-7		22
1517	Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. <b>2007</b> , 13, 655-64		121
1516	Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. <b>2007</b> , 13, 724-33		13
1515	Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. <b>2007</b> , 39, 297-306		8
1514	Acute myeloid leukemia and the position of autologous stem cell transplantation. <b>2007</b> , 44, 259-66		34
1513	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. <i>Blood</i> , <b>2007</b> , 110, 1648-55	2.2	77
1512	Clinicopathologic analysis of acute myeloid leukemia in a single institution: biphenotypic acute myeloid leukemia may not be an aggressive subtype. <b>2007</b> , 70, 269-73		9
1511	Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. <b>2007</b> , 86, 422-8		9

1510	Microarray Technology and Cancer Gene Profiling. <b>2007,</b>	4
1509	Acute Myelogenous Leukemia. <b>2007,</b>	
1508	David Galton--the thesis years. <b>2007, 48, 2290-1</b>	
1507	Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. <b>2007, 48, 72-9</b>	5
1506	Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. <b>2007, 48, 2145-51</b>	25
1505	Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil. <b>2007, 48, 2381-6</b>	14
1504	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. <b>2007, 25, 4246-54</b>	320
1503	FISH panels for hematologic malignancies. <b>2007, 118, 284-96</b>	30
1502	LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenous leukemia patients and protects leukemia cells from apoptosis in vitro. <b>2007, 6, 31</b>	47
1501	Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. <b>2007, 20, 125-54</b>	22
1500	Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. <b>2007, 20, 29-37</b>	60
1499	Management of Haematological Malignancies. <b>2007,</b>	1
1498	[Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia]. <b>2007, 27, 229-36</b>	8
1497	[Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia]. <b>2007, 27, 305-12</b>	2
1496	The Association between Cytogenetic Abnormalities and Clinical Outcomes Based on Prognostic Factors of the Children Cancer Group (CCG) in Pediatric Patients with Acute Leukemia: Two Institutional Retrospective Studies. <b>2007, 42, 206</b>	
1495	Topoisomerase II $\alpha$ mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. <b>2007,</b>	
1494	Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia. <b>2007, 2, 117727190700200</b>	6
1493	. <b>2007,</b>	36



1492	Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia. <b>2007</b> , 82, 6-14	4
1491	Benzene-induced acute myeloid leukemia: a clinician's perspective. <b>2007</b> , 82, 826-30	33
1490	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. <b>2007</b> , 82, 867-72	46
1489	Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). <b>2007</b> , 82, 1056-62	18
1488	Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. <b>2007</b> , 25, 1-5	22
1487	The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. <b>2007</b> , 25, 38-43	31
1486	Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. <b>2007</b> , 25, 84-9	9
1485	Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. <b>2007</b> , 25, 170-7	7
1484	Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. <b>2007</b> , 46, 359-72	22
1483	Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. <b>2007</b> , 110, 345-52	92
1482	Progress in the treatment of acute myeloid leukemia. <b>2007</b> , 110, 1900-10	68
1481	Allogeneic hematopoietic stem cell transplantation in the elderly. <b>2007</b> , 64, 49-63	27
1480	Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. <b>2007</b> , 31, 39-47	18
1479	Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome. <b>2007</b> , 31, 67-73	13
1478	CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. <b>2007</b> , 31, 157-62	34
1477	Detection of the CBFβ/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients. <b>2007</b> , 31, 471-6	15
1476	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. <b>2007</b> , 31, 947-53	33
1475	Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). <b>2007</b> , 31, 791-7	7

1474	Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. <b>2007</b> , 31, 1253-7	3
1473	Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. <b>2007</b> , 31, 1383-8	29
1472	Human T cell leukemia virus type 1 Tax-induced signals in cell survival, proliferation, and transformation. <b>2007</b> , 7, 34-52	6
1471	East and west together. Abstracts of the Leukemia and Lymphoma Meeting. Dubrovnik, Croatia. September 15-19, 2007. <b>2007</b> , 31 Suppl 2, S3-117	
1470	Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. <b>2007</b> , 7, 270-80	598
1469	Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. <b>2007</b> , 40, 349-54	19
1468	Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. <b>2007</b> , 40, 753-8	8
1467	Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. <b>2007</b> , 21, 480-8	17
1466	Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. <b>2007</b> , 21, 453-61	65
1465	DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. <b>2007</b> , 21, 1224-31	50
1464	The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. <b>2007</b> , 21, 1177-82	52
1463	Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. <b>2007</b> , 21, 2495-505	67
1462	Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. <b>2007</b> , 17, 274-6	43
1461	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <b>2007</b> , 136, 87-95	17
1460	Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. <b>2007</b> , 136, 96-105	49
1459	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <b>2007</b> , 136, 590-6	63
1458	CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. <b>2007</b> , 136, 597-608	36
1457	Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. <b>2007</b> , 137, 387-400	88

1456	Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. <b>2007</b> , 138, 624-31	30
1455	Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. <b>2008</b> , 140, 71-9	28
1454	From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. <b>2007</b> , 28, 1434-49	7
1453	A new cytogenetic abnormality, t(2;7)(q33;q36), in acute promyelocytic leukemia. <b>2007</b> , 173, 71-4	1
1452	Acute myeloid leukemia (AML-M2) with t(5;11)(q35;q13) and normal expression of cyclin D1. <b>2007</b> , 172, 154-7	7
1451	A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. <b>2007</b> , 173, 17-22	9
1450	Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. <b>2007</b> , 174, 138-46	11
1449	Molecular cytogenetic analysis of complex karyotypes with derivative chromosome der(1)t(1;5) found in two patients with myeloid leukemia. <b>2007</b> , 176, 150-5	2
1448	Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. <b>2007</b> , 177, 64-9	6
1447	Novel therapeutic agents in acute myeloid leukemia. <b>2007</b> , 35, 163-6	21
1446	Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. <b>2007</b> , 35, 1668-76	35
1445	An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. <b>2007</b> , 78, 41-7	2
1444	Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. <b>2007</b> , 78, 477-86	17
1443	The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). <b>2007</b> , 78, 468-76	33
1442	Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. <b>2007</b> , 79, 17-24	21
1441	Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. <b>2007</b> , 25, 1853-61	47
1440	Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. <i>Blood</i> , <b>2007</b> , 109, 874-85	2.2 415
1439	Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia. <b>2007</b> , 136, 510-2	4

1438	Acute myeloid leukemia with multilineage dysplasia in children. <b>2007</b> , 86, 358-63	5
1437	Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). <b>2007</b> , 86, 343-7	4
1436	Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia. <b>2007</b> , 86, 143-6	14
1435	Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). <b>2007</b> , 24, 907-20	4
1434	Low frequency of KIT gene mutation in pediatric acute myeloid leukemia with inv(16)(p13q22): A study of the Japanese childhood AML cooperative study group. <b>2007</b> , 86, 289-290	5
1433	[Pathobiology of acute myeloid leukemia]. <b>2007</b> , 102, 290-5	4
1432	[Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. <b>2007</b> , 102, 296-308	0
1431	Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. <b>2007</b> , 86, 311-27	39
1430	Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. <b>2007</b> , 86, 425-8	18
1429	Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. <b>2007</b> , 86, 741-7	23
1428	Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature. <b>2006</b> , 25, 507-19	10
1427	Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. <b>2007</b> , 7, 102-7	3
1426	New approaches for the detection of minimal residual disease in acute myeloid leukemia. <b>2007</b> , 2, 111-8	4
1425	Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells. <b>2008</b> , 87, 195-203	14
1424	ACUTE LEUKEMIAS XII. <b>2008</b> , 87, 21-98	1
1423	Cytogenetic features in myelodysplastic syndromes. <b>2008</b> , 87, 515-26	148
1422	Childhood acute myeloid leukemia. <b>2008</b> , 9, 95-105	26
1421	Interstitial deletion of 9q in a case of acute myeloid leukemia with t(8;21). <b>2008</b> , 24, 75-7	1

1420	Recent advances in management of acute myeloid leukemia (AML). <b>2008</b> , 75, 831-7	11
1419	Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. <b>2008</b> , 87, 144-151	17
1418	Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. <b>2008</b> , 87, 195-202	11
1417	Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. <b>2008</b> , 88, 154-158	9
1416	An analysis of complex chromosomal aberrations in seven cases of myelodysplastic syndromes by M-FISH and whole chromosome painting. <b>2008</b> , 88, 369-373	5
1415	Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2). <b>2008</b> , 50, 651-4	
1414	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. <b>2008</b> , 50, 542-8	1
1413	Aggressive natural killer cell leukemia presenting with hemophagocytic lymphohistiocytosis. <b>2008</b> , 50, 654-7	11
1412	Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. <b>2008</b> , 112, 407-15	96
1411	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. <b>2008</b> , 113, 376-82	82
1410	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <b>2008</b> , 113, 1933-52	74
1409	Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. <b>2008</b> , 113, 1370-8	144
1408	The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. <b>2008</b> , 113, 1605-13	81
1407	Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants. <b>2008</b> , 74, 9-16	5
1406	CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes. <b>2008</b> , 123, 2321-6	8
1405	Identification of genes with abnormal expression changes in acute myeloid leukemia. <b>2008</b> , 47, 8-20	130
1404	Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. <b>2008</b> , 47, 288-98	47
1403	Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. <b>2008</b> , 47, 729-39	70

1402	Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. <b>2008</b> , 83, 54-8	22
1401	Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. <b>2008</b> , 83, 831-4	7
1400	Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality. <b>2008</b> , 83, 846-9	18
1399	Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. <b>2008</b> , 32, 407-11	14
1398	Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. <b>2008</b> , 32, 1221-7	68
1397	Clinically useful prognostic factors in acute myeloid leukemia. <b>2008</b> , 66, 181-93	58
1396	Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. <b>2008</b> , 22, 221-34	36
1395	Molecular diagnostics in haematopathology. <b>2008</b> , 14, 223-235	3
1394	Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. <b>2008</b> , 87, 382-386	0
1393	Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. <b>2008</b> , 22, 1576-86	102
1392	Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. <b>2008</b> , 22, 1395-401	32
1391	Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. <b>2008</b> , 22, 1539-41	175
1390	HOX expression patterns identify a common signature for favorable AML. <b>2008</b> , 22, 2041-7	101
1389	Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. <b>2008</b> , 22, 1874-81	17
1388	Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. <b>2008</b> , 21, 1029-36	23
1387	DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. <b>2008</b> , 456, 66-72	1064
1386	Current status of blood and marrow transplantation for patients with AML. <b>2008</b> , 42 Suppl 1, S14-S17	1
1385	Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. <b>2008</b> , 42, 145-57	29

1384	Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. <b>2008</b> , 42, 659-66	9
1383	Place of HSCT in treatment of childhood AML. <b>2008</b> , 42 Suppl 2, S7-9	16
1382	Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. <b>2008</b> , 27, 2249-56	24
1381	Abstracts of the XXist International Symposium on Technological Innovations in Laboratory Hematology. April 28-May 1, 2008. Sydney, Australia. <b>2008</b> , 30 Suppl 1, 1-147	3
1380	Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. <b>2008</b> , 27, 4933-42	15
1379	Review: genetic models of acute myeloid leukaemia. <b>2008</b> , 27, 3765-79	40
1378	Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. <b>2008</b> , 27, 5759-73	47
1377	High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. <b>2008</b> , 41, 721-7	53
1376	Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan. <b>2008</b> , 22, 428-32	12
1375	Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH). <b>2008</b> , 22, 132-7	18
1374	Genetics of therapy-related myelodysplasia and acute myeloid leukemia. <b>2008</b> , 22, 240-8	180
1373	Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia. <b>2008</b> , 30, 286-91	32
1372	Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. <b>2008</b> , 141, 782-91	65
1371	KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. <b>2008</b> , 85, 227-31	13
1370	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <b>2008</b> , 8, 195	36
1369	MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. <b>2008</b> , 36, 433-42	76
1368	Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. <b>2008</b> , 76, 1417-25	27
1367	Cytogenetic and genomic characterization of cell line ARH77. <b>2008</b> , 181, 40-5	



1366	Trisomies 4 and 10 in acute myeloid leukemia: report of a new case. <b>2008</b> , 185, 55-6	1
1365	Specific chromosomal aberrations in de novo acute myeloid leukemia: a comparative analysis of results with a report of three novel chromosomal rearrangements t(7;14)(q35;q13), t(8;18)(p11.2;q12), t(13;15) in Indian population. <b>2008</b> , 32, 168-77	4
1364	Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. <b>2008</b> , 35, 365-77	114
1363	Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. <b>2008</b> , 12, 889-98	37
1362	Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. <b>2008</b> , 80, 197-200	56
1361	Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. <b>2008</b> , 80, 201-7	24
1360	Myeloablative unrelated cord blood transplantation for adult acute myeloid leukemia patients with 11q23 abnormalities. <b>2008</b> , 80, 545-8	3
1359	Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. <b>2008</b> , 81, 112-22	73
1358	Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia. <b>2008</b> , 81, 273-80	9
1357	Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. <b>2008</b> , 81, 454-60	18
1356	New approaches in acute myeloid leukemia. <b>2008</b> , 21, 29-41	7
1355	Clinical progress in acute myeloid leukemia. Preface. <b>2008</b> , 21, 597-9	1
1354	Tumor suppressor gene inactivation in myeloid malignancies. <b>2008</b> , 21, 601-14	6
1353	Fluorescence In Situ Hybridization (FISH) and Conventional Cytogenetics for Hematology and Oncology Diagnosis. <b>2008</b> , 303-364	
1352	Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. <b>2008</b> , 10, 198-202	16
1351	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <b>2008</b> , 358, 1909-18	1330
1350	A $\geq 1$ log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. <b>2008</b> , 49, 517-23	40
1349	A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. <b>2008</b> , 14, 28-35	48

1348	HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. <b>2008</b> , 14, 187-96		41
1347	Indications for hematopoietic cell transplantation in acute leukemia. <b>2008</b> , 14, 154-64		7
1346	Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. <b>2008</b> , 14, 1262-9		22
1345	Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. <b>2008</b> , 40, 192-9		38
1344	Myelodysplastic syndrome in children and adolescents. <b>2008</b> , 45, 60-70		43
1343	Whole genome scanning as a cytogenetic tool in hematologic malignancies. <i>Blood</i> , <b>2008</b> , 112, 965-74	2.2	116
1342	Acute myeloid leukemia. <b>2008</b> , 55, 21-51, ix		45
1341	The genetics of cancer survivorship. <b>2008</b> , 22, 257-69, vi-vii		2
1340	Can the influence of karyotype in acute myeloid leukemia be overcome by high-dose chemotherapy?. <b>2008</b> , 49, 2227-8		
1339	Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. <b>2008</b> , 49, 1132-41		40
1338	Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. <b>2008</b> , 49, 2284-90		2
1337	Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. <b>2008</b> , 49, 1123-31		16
1336	Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <b>2008</b> , 8, 785-98		5
1335	A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. <b>2008</b> , 10, 236-41		28
1334	Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. <b>2008</b> , 3, e2141		218
1333	Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. <b>2008</b> , 26, 5192-7		68
1332	Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. <b>2008</b> , 26, 4944-51		142
1331	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <b>2008</b> , 93, 1025-32		13

1330	Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia. <b>2008</b> , 13, 95-100	12
1329	An unusual case of febrile neutropenia: acute myeloid leukemia presenting as myeloid sarcoma of the spleen. <b>2008</b> , 100, 957-9	3
1328	Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. <b>2008</b> , 13, 142-6	21
1327	Trisomy 22 as the sole abnormality is an important marker for the diagnosis of acute myeloid leukemia with inversion 16. <b>2008</b> , 31, 440-4	4
1326	Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. <b>2008</b> , 26, 3183-8	63
1325	Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. <b>2008</b> , 400-11	57
1324	Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia. <b>2008</b> , 61, 903-8	6
1323	Current and emerging strategies for the management of acute myeloid leukemia in the elderly. <b>2008</b> , 13, 1097-108	21
1322	Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. <b>2008</b> , 14, 924-30	19
1321	The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. <b>2008</b> , 14, 721-30	35
1320	Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <b>2008</b> , 26, 4595-602	200
1319	Del(5q) is associated with clinical and histological parameters in small cell neuroendocrine lung carcinoma. <b>2008</b> , 16, 419-23	7
1318	Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. <b>2008</b> , 26, 4791-7	453
1317	Mutations in myeloid neoplasms. <b>2008</b> , 17, 191-9	2
1316	Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. <b>2008</b> , 49, 508-16	28
1315	Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. <b>2008</b> , 49, 524-30	23
1314	Bersicht Diagnostik der akuten myeloischen Leukämie. <b>2008</b> , 29, 188-190	
1313	The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. <b>2008</b> , 16, 439-49	51

1312	Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. <i>Blood</i> , <b>2008</b> , 111, 2527-37	2.2	290
1311	Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. <i>Blood</i> , <b>2008</b> , 111, 4322-8	2.2	106
1310	Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 1993-2003	2.2	83
1309	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 111, 4788-96	2.2	77
1308	Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. <i>Blood</i> , <b>2008</b> , 111, 4338-47	2.2	72
1307	MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. <i>Blood</i> , <b>2008</b> , 111, 1855-61	2.2	54
1306	Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. <i>Blood</i> , <b>2008</b> , 112, 568-75	2.2	308
1305	Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. <i>Blood</i> , <b>2008</b> , 112, 2139-48	2.2	39
1304	Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 112, 814-21	2.2	88
1303	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 112, 4193-201	2.2	281
1302	Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 112, 3391-402	2.2	44
1301	Chromosomal translocations: revisited yet again. <i>Blood</i> , <b>2008</b> , 112, 2183-9	2.2	113
1300	Isolated Myeloid Sarcoma of the Small Intestine in an Aleukemic Patient &ndash; Case Report and Review of the Literature. <b>2008</b> , 24, 171-174		
1299	Optimizing therapy for acute myeloid leukemia. <b>2008</b> , 6, 1003-16		15
1298	Post-remission therapy in acute myeloid leukemia: what should I do now?. <b>2008</b> , 93, 801-5		1
1297	The challenge of risk stratification in acute myeloid leukemia with normal karyotype. <b>2008</b> , 1, 141-58		13
1296	Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town. <b>2008</b> , 1, 80-9		2
1295	Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. <b>2008</b> , 19, 45-54		11

1294	Alternative donor transplants for high-risk acute myeloid leukemia. <b>2008</b> , 15, 115-20		4
1293	Granulocytic sarcoma of the colon in a child with acute myeloid leukemia presenting as hematochezia. <b>2008</b> , 30, 981-3		6
1292	Bussulfano e melfalano como regime de condicionamento para o transplante autogênico de células-tronco hematopólicas na leucemia mielóide aguda em primeira remissão completa. <b>2008</b> , 30,		
1291	Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. <b>2008</b> , 23, 833-7		11
1290	Leucemia mielóide aguda: o olhar dos anos 2000 no Serviço de Hematologia do Hospital de Clínicas de Porto Alegre-RS. <b>2008</b> , 30,		1
1289	Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. <b>2008</b> , 93, 1769-72		37
1288	Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. <b>2008</b> , 9, 2194-204		12
1287	Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. <b>2008</b> , 13, 4605-16		7
1286	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. <b>2009</b> , 4, 197-205		14
1285	[Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia]. <b>2009</b> , 29, 371-8		7
1284	Treatment strategies for pediatric acute myeloid leukemia. <b>2009</b> , 10, 57-79		8
1283	Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. <i>Blood</i> , <b>2009</b> , 113, 2096-103	2.2	49
1282	Bone Marrow. <b>2009</b> , 1536-1593		
1281	Mouse models of human AML accurately predict chemotherapy response. <b>2009</b> , 23, 877-89		197
1280	Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies. <b>2009</b> , 8, 184-93		5
1279	Place de la biologie moléculaire dans l'évaluation pronostique des patients atteints de leucémie aiguë myéloïde. <b>2009</b> , 15, 426-443		
1278	Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <b>2009</b> , 27, 3000-6		73
1277	New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. <b>2009</b> , 27, 5219-26		99

1276	Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. <b>2009</b> , 86, 813-22	24
1275	Independent prognostic factors for AML outcome. <b>2009</b> , 385-95	120
1274	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. <b>2009</b> , 16, 92-7	25
1273	Treatment of acute myeloid leukemia. <b>2009</b> , 94, 10-6	42
1272	Targeted therapy in acute myeloid leukaemia: current status and future directions. <b>2009</b> , 18, 433-55	31
1271	Acute myeloid leukemia. <b>2009</b> , 25-33	
1270	Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. <b>2009</b> , 69, 8652-61	60
1269	Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <b>2009</b> , 27, 3198-204	135
1268	World Health Organization sub-types, initial treatment outcome and prognostic study of unselected adult patients with acute myeloid leukaemia in Shanghai: an analysis of 623 cases. <b>2009</b> , 37, 1191-201	5
1267	Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. <b>2009</b> , 131, 647-55	60
1266	Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. <b>2009</b> , 27, 4392-7	66
1265	Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. <b>2009</b> , 15, 7291-8	18
1264	Acute leukaemias. <b>2009</b> , 37, 190-194	2
1263	Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. <b>2009</b> , 83, 99-107	32
1262	Cytogenetics of pediatric acute myeloid leukemia. <b>2009</b> , 83, 391-405	46
1261	The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. <b>2009</b> , 83, 439-48	30
1260	Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. <b>2009</b> , 37, 450-60	29
1259	Proteomics-based prediction of clinical response in acute myeloid leukemia. <b>2009</b> , 37, 784-90	10

1258	Acute myelogenous leukemia. <b>2009</b> , 37, 649-58	147
1257	Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6. <b>2009</b> , 189, 48-52	7
1256	Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. <b>2009</b> , 193, 44-53	16
1255	Novel t(8;17)(q23;q24.2) and t(9;22)(p24.1;q12.2) in acute megakaryoblastic leukemia AML-M7 subtype in an adult patient. <b>2009</b> , 193, 112-5	4
1254	Acute leukemia in adolescents and young adults. <b>2009</b> , 36, 213-26	35
1253	Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. <b>2009</b> , 84, 79-86	28
1252	Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia. <b>2009</b> , 84, 87-92	21
1251	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. <b>2009</b> , 84, 530-32	28
1250	Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. <b>2009</b> , 84, 524-6	14
1249	DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing?. <b>2009</b> , 84, 526-9	17
1248	FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. <b>2009</b> , 84, 532-5	15
1247	Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. <b>2009</b> , 84, 535-8	9
1246	Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). <b>2009</b> , 84, 538-40	18
1245	Blast phase of essential thrombocythemia: A single center study. <b>2009</b> , 84, 641-4	7
1244	Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. <b>2009</b> , 27, 90-7	24
1243	Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. <b>2009</b> , 27, 198-202	10
1242	Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. <b>2009</b> , 27, 171-81	99
1241	Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. <b>2010</b> , 28, 3-12	5



1240	The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. <b>2010</b> , 28, 13-9	34
1239	Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. <b>2009</b> , 115, 3719-27	64
1238	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. <b>2009</b> , 115, 5746-51	83
1237	Hämatopoetische Stammzelltransplantation. <b>2009</b> , 15, 564-574	
1236	Molecular diagnostics of acute myeloid leukaemia. <b>2009</b> , 15, 531-539	2
1235	Unbalanced jumping translocation involving 3q in myeloproliferative disease. <b>2009</b> , 26, 251-5	4
1234	MicroRNA expression in acute myeloid leukemia. <b>2009</b> , 4, 83-8	36
1233	Biologie und risikoadaptierte Therapie der akuten myeloischen Leukämie. <b>2009</b> , 2, 67-72	
1232	Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. <b>2009</b> , 15, 193-7	3
1231	Tailored therapeutic approaches in acute myeloid leukaemia. <b>2009</b> , 2, 18-21	
1230	Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures. <b>2009</b> , 58, 1679-90	5
1229	Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. <b>2009</b> , 88, 151-8	24
1228	Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. <b>2009</b> , 145, 598-605	192
1227	Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. <b>2009</b> , 145, 749-60	14
1226	Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. <b>2009</b> , 146, 54-63	30
1225	Successful routine cytogenetic analysis from trephine biopsy specimens following failure to aspirate bone marrow. <b>2009</b> , 146, 573	6
1224	The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. <b>2009</b> , 23, 656-63	109
1223	Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. <b>2009</b> , 23, 1801-6	48

1222	Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. <b>2009</b> , 43, 709-15	28
1221	CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. <b>2009</b> , 43, 399-410	45
1220	Interactive diagnostics in the indication to allogeneic SCT in AML. <b>2009</b> , 43, 745-56	14
1219	Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. <b>2009</b> , 44, 589-94	8
1218	Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response. <b>2009</b> , 276, 6810-22	12
1217	The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. <b>2009</b> , 31, 61-8	7
1216	Development of a biochip-based assay integrated in a global strategy for identification of fusion transcripts in acute myeloid leukemia: a work flow for acute myeloid leukemia diagnosis. <b>2010</b> , 32, 398-409	4
1215	Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. <b>2009</b> , 33, 426-33	10
1214	Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. <b>2009</b> , 33, 443-9	19
1213	Derivative (7)t(7;8): The sole karyotype abnormality in acute promyelocytic leukemia with PML/RARA rearrangement identified by RT-PCR and sequence analysis. <b>2009</b> , 33, e55-8	4
1212	Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. <b>2009</b> , 33, 1072-8	7
1211	Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. <b>2009</b> , 33, 891-7	26
1210	Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. <b>2009</b> , 33, 1189-93	16
1209	Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. <b>2009</b> , 33, 1650-7	12
1208	Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. <b>2009</b> , 23, 2275-80	56
1207	Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. <b>2010</b> , 145, 67-83	15
1206	Molecular diagnostics in acute leukemias. <b>2009</b> , 47, 1333-41	28
1205	MicroRNA expression profiling in bone marrow: implications in hematological malignancies. <b>2009</b> , 4, 88-97	4

1204	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. <b>2009</b> , 27, 5195-201		337
1203	Leukemia. <b>2009</b> ,		1
1202	Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. <b>2009</b> , 45, 1692-9		58
1201	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. <b>2009</b> , 22, 239-48		21
1200	Prognostic factors in AML in relation to (ab)normal karyotype. <b>2009</b> , 22, 523-8		19
1199	Advances and controversies in the biology and therapy of acute leukaemia and myelodysplasia. <b>2009</b> , 22, 475-8		
1198	CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. <b>2009</b> , 138, 286-99		1011
1197	Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. <b>2009</b> , 15, 1306-13		13
1196	Trithorax, Hox, and TALE-class homeodomain proteins ensure cell survival through repression of the BH3-only gene egl-1. <b>2009</b> , 329, 374-85		34
1195	Humanized model to study leukemic stem cells. <b>2009</b> , 538, 247-62		5
1194	Next-generation sequencing of cancer genomes: back to the future. <b>2009</b> , 6, 653		20
1193	Chromosomal translocations in AML: detection and prognostic significance. <b>2010</b> , 145, 41-58		7
1192	Acute promyelocytic leukemia: a paradigm for differentiation therapy. <b>2010</b> , 145, 219-35		50
1191	Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. <i>Blood</i> , <b>2009</b> , 114, 3064-73	2.2	126
1190	Bioinformatics in Cancer and Cancer Therapy. <b>2009</b> ,		1
1189	The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <b>2009</b> , 3, 47-57		
1188	Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. <i>Blood</i> , <b>2009</b> , 113, 6558-66	2.2	132
1187	Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. <b>2009</b> , 50, 1512-8		4

1186	Dicentric t(8;13)(q10;q10) as an additional chromosomal abnormality in a case of acute promyelocytic leukemia with very poor outcome. <b>2009</b> , 50, 287-9		2
1185	Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. <b>2009</b> , 27, 4007-13		186
1184	Update on genetic and molecular markers associated with myelodysplastic syndromes. <b>2009</b> , 50, 341-8		6
1183	Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia. <b>2009</b> , 3, 14-19		
1182	Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. <b>2009</b> , 3, E11-E21		2
1181	Monitoring of minimal residual disease in acute myeloid leukemia. <b>2009</b> , 21, 582-8		22
1180	Acute leukemia in patients sixty years of age and older: a twenty year single institution review. <b>2009</b> , 32, 137-41		4
1179	FLT3 inhibition as a targeted therapy for acute myeloid leukemia. <b>2009</b> , 21, 594-600		43
1178	Sustained remission achieved with ATRA and chemotherapy in second relapse of acute promyelocytic leukemia in Down syndrome. <b>2009</b> , 31, 539-40		3
1177	Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. <b>2009</b> , 16, 98-104		44
1176	Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. <b>2009</b> , 94, 213-23		62
1175	Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. <b>2009</b> , 94, 46-53		13
1174	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. <i>Blood</i> , <b>2009</b> , 113, 5090-3	2.2	75
1173	Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. <i>Blood</i> , <b>2009</b> , 113, 1002-5	2.2	64
1172	Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. <i>Blood</i> , <b>2009</b> , 113, 2145-53	2.2	71
1171	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. <i>Blood</i> , <b>2009</b> , 113, 28-36	2.2	162
1170	Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. <i>Blood</i> , <b>2009</b> , 113, 1432-43	2.2	87
1169	Identification of AML1-ETO modulators by chemical genomics. <i>Blood</i> , <b>2009</b> , 113, 6193-205	2.2	33

1168	Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. <i>Blood</i> , <b>2009</b> , 113, 3666-72	2.2	99
1167	Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. <i>Blood</i> , <b>2009</b> , 114, 4859-70	2.2	51
1166	Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. <i>Blood</i> , <b>2009</b> , 114, 3793-802	2.2	97
1165	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , <b>2009</b> , 114, 2489-96	2.2	313
1164	High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. <i>Blood</i> , <b>2009</b> , 114, 2993-3000	2.2	46
1163	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. <i>Blood</i> , <b>2009</b> , 114, 3983-93	2.2	63
1162	Predictive factors of response and survival following chemotherapy treatment in acute myeloid leukemia progression from myelodysplastic syndrome. <b>2009</b> , 48, 1629-33		4
1161	Molecular genetics in acute myeloid leukemia. <b>2010</b> , 22, 646-55		59
1160	Acute Myeloid Leukemia and Myelodysplastic Disorders. <b>2010</b> , 95-108		1
1159	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. <b>2010</b> , 95, 1420-4		17
1158	Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. <b>2010</b> , 95, 989-95		56
1157	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. <b>2010</b> , 95, 1754-61		62
1156	Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 115, 636-42	2.2	121
1155	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. <i>Blood</i> , <b>2010</b> , 115, 948-56	2.2	90
1154	Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. <i>Blood</i> , <b>2010</b> , 115, 2372-9	2.2	135
1153	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. <i>Blood</i> , <b>2010</b> , 115, 1985-92	2.2	87
1152	Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 115, 1850-7	2.2	145
1151	Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. <i>Blood</i> , <b>2010</b> , 116, 4958-67	2.2	64

1150	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. <i>Blood</i> , <b>2010</b> , 116, 2779-82	2.2	105
1149	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 116, 4422-9	2.2	280
1148	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. <i>Blood</i> , <b>2010</b> , 116, 1839-48	2.2	141
1147	Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. <i>Blood</i> , <b>2010</b> , 116, 3766-9	2.2	81
1146	How I treat acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 116, 3147-56	2.2	133
1145	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 116, 2295-303	2.2	96
1144	Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. <i>Blood</i> , <b>2010</b> , 116, 2224-8	2.2	157
1143	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <b>2010</b> , 95, 424-31		72
1142	Cytogenetics. 71-89		1
1141	Phenomenon of evolution of clonal chromosomal abnormalities in childhood acute myeloid leukemia. <b>2010</b> , 44, 160-169		1
1140	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2010</b> , 115, 453-74	2.2	2483
1139	Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. <b>2010</b> , 89, 225-8		7
1138	Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML. <b>2010</b> , 89, 459-67		13
1137	Trisomy 9 in a Patient with Acute Myelogenous Leukaemia FAB Type M2: A Rare Occurrence. <b>2010</b> , 26, 103-5		2
1136	Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. <b>2010</b> , 91, 276-83		23
1135	Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. <b>2010</b> , 91, 310-21		
1134	Ring/marker chromosome derived from chromosome 7 in childhood acute megakaryoblastic leukemia with monosomy 7. <b>2010</b> , 92, 386-90		6
1133	Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. <b>2010</b> , 179, 507-10		2

1132	Acute myeloid leukemia: when to transplant in first complete remission. <b>2010</b> , 5, 101-8	9
1131	Prognostic factors in pediatric acute myeloid leukemia. <b>2010</b> , 5, 200-6	30
1130	Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. <b>2010</b> , 10, 377	23
1129	Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study. <b>2010</b> , 10, 514	12
1128	Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma. <b>2010</b> , 3, 25	10
1127	Concomitant and successive amplifications of MYC in APL-like leukemia. <b>2010</b> , 197, 75-80	12
1126	Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. <b>2010</b> , 202, 108-22	25
1125	Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. <b>2010</b> , 202, 101-7	12
1124	DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. <b>2010</b> , 17, 13-27	640
1123	Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. <b>2010</b> , 84, 128-32	11
1122	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. <b>2010</b> , 84, 191-200	21
1121	Reasons for treating secondary AML as de novo AML. <b>2010</b> , 85, 217-26	40
1120	Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. <b>2010</b> , 116, 1725-32	22
1119	Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. <b>2010</b> , 116, 5272-8	8
1118	Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). <b>2010</b> , 85, 477-81	11
1117	Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. <b>2010</b> , 85, 687-90	7
1116	BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. <b>2010</b> , 34, 166-72	24
1115	Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line. <b>2010</b> , 34, 261-2	13



1114	Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. <b>2010</b> , 34, 1358-65	24
1113	Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. <b>2010</b> , 34, 942-5	30
1112	Granulocytic sarcoma of the pancreas: a case report and review of the literatures. <b>2010</b> , 10, 80	19
1111	Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. <b>2010</b> , 55, 421-9	80
1110	Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. <b>2010</b> , 148, 217-25	54
1109	Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. <b>2010</b> , 151, 447-59	38
1108	OGG1 is a novel prognostic indicator in acute myeloid leukaemia. <b>2010</b> , 29, 2005-12	27
1107	Array-based genomic resequencing of human leukemia. <b>2010</b> , 29, 3723-31	211
1106	Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. <b>2010</b> , 24, 205-9	7
1105	Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. <b>2010</b> , 24, 1422-8	100
1104	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. <b>2010</b> , 24, 1290-8	120
1103	Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition. <b>2010</b> , 75, 1650-66	16
1102	Activated leukemic oncogenes responsible for neoplastic transformation of hematopoietic cells. <b>2010</b> , 44, 369-379	3
1101	Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. <b>2010</b> , 45, 165-70	20
1100	BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. <b>2010</b> , 45, 640-6	14
1099	Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. <b>2010</b> , 45, 69-77	9
1098	Multiplex fluorescence in situ hybridization in identifying chromosome involvement of complex karyotypes in de novo myelodysplastic syndromes and acute myeloid leukemia. <b>2010</b> , 32, e86-95	8
1097	Management of acute myeloid leukemia in older adults. 245-259	

1096 Blood Disorders in the Elderly. **2010**, 775-790

1095 In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. **2010**, 5, e12464 20

1094 Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission. **2010**, 45, 95-101 1

1093 Transplante de células-tronco hematopoiéticas e leucemia mieloide aguda: diretrizes brasileiras. **2010**, 32, 61-65 2

1092 High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. **2010**, 25, 841-5 17

1091 Identification of gene networks associated with acute myeloid leukemia by comparative molecular methylation and expression profiling. **2010**, 2, 43-55 3

1090 [A case of del(16)(q22) in a patient with acute myeloid leukemia with complex karyotype]. **2010**, 30, 329-33

1089 Level of HOXA5 hypermethylation in acute myeloid leukemia is associated with short-term outcome. **2010**, 30, 469-73 10

1088 Leucémie aiguë myéloïde de l'adulte. **2010**, 16, 20-23

1087 Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. **2010**, 28, 2682-9 161

1086 Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. **2010**, 2, 17ra9 289

1085 Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. **2010**, 28, 3872-9 59

1084 NF1 inactivation in adult acute myelogenous leukemia. **2010**, 16, 4135-47 54

1083 Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. **2010**, 16, 3721-33 50

1082 Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. **2010**, 28, 586-95 174

1081 Older patients with acute myeloid leukemia. **2010**, 3, 755-74 2

1080 Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. **2010**, 28, 2674-81 217

1079 Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. **2010**, 95, 1857-64 84

1078	Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment. <b>2010</b> , 40, 556-66		8
1077	Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. <b>2010</b> , 133, 34-40		26
1076	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 116, 1747-54	2.2	65
1075	Acute Myelogenous Leukemia. <b>2010</b> ,		
1074	Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. <b>2010</b> , 45, 1154-60		3
1073	Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. <b>2010</b> , 45, 1611-7		8
1072	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. <b>2010</b> , 207, 2581-94		54
1071	WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. <b>2010</b> ,		
1070	Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. <i>Blood</i> , <b>2010</b> , 116, 354-65	2.2	1353
1069	Acute Myeloid Leukemia. <b>2010</b> , 45-139		1
1068	High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. <b>2010</b> , 24, 2048-55		23
1067	Laromustine (cloretazine). <b>2010</b> , 11, 657-67		4
1066	Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. <b>2010</b> , 28, 4642-8		178
1065	Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <b>2010</b> , 165-176		
1064	Mouse Models of Myeloid Leukemia. <b>2010</b> , 597-610		
1063	Molecular mechanisms involved in the progression of myelodysplastic syndrome. <b>2010</b> , 6, 445-55		25
1062	Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. <b>2010</b> , 28, 2739-47		216
1061	Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. <b>2010</b> , 304, 2706-15		254

1060	Cord blood transplantation in adults with acute myeloid leukaemia. <b>2010</b> , 23, 197-206		4
1059	The evolving paradigm of prognostic factors in AML: Introduction to the Acute Leukemia Forum 2010. <b>2010</b> , 23, 453-6		1
1058	Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. <b>2010</b> , 16, 1018-24		12
1057	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. <b>2010</b> , 28, 3717-23		157
1056	Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. <b>2010</b> , 12, 441-52		9
1055	Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. <b>2010</b> , 45, 877-85		43
1054	Techniques to Determine Clonality in Hematolymphoid Malignancies. <b>2010</b> , 119-128		1
1053	Genomics in Leukemias. <b>2010</b> , 421-431		
1052	Acute myeloid leukemia. <b>2010</b> , 24, 35-63		99
1051	A new reliable fluorescence in situ hybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. <b>2010</b> , 51, 680-5		3
1050	Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. <b>2010</b> , 28, 63-73		18
1049	Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. <b>2011</b> , 28, 269-78		8
1048	A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. <i>Blood</i> , <b>2011</b> , 117, 2366-72	2.2	125
1047	Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. <b>2011</b> , 52, 642-7		5
1046	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <b>2011</b> , 96, 375-83		186
1045	Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: determination of incidence, distribution patterns, and report of a novel KIT mutation. <b>2011</b> , 52, 865-76		8
1044	Low dose cytarabine monotherapy for acute myeloid leukaemia. <b>2011</b> ,		
1043	Therapeutic advances in acute myeloid leukemia. <b>2011</b> , 29, 487-94		581

1042	Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. <b>2011</b> , 11, 433-8		41
1041	Prognostic factors in adult acute leukemia. <b>2011</b> , 25, 1163-87		8
1040	Cytogenetic analysis and reporting. <b>2011</b> , 730, 259-68		2
1039	[From conventional cytogenetics to microarrays. Fifty years of Philadelphia chromosome]. <b>2011</b> , 137, 221-9		2
1038	Acute myeloid leukaemia: optimal management and recent developments. <b>2011</b> , 71, 1537-50		16
1037	Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. <b>2011</b> , 25, 1189-213		5
1036	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. <i>Blood</i> , <b>2011</b> , 117, 2358-65	2.2	174
1035	Making a meal of multiple mutations in acute myeloid malignancies. <b>2011</b> , 13, 605-8		
1034	Cancer Cytogenetics. <b>2011</b> ,		1
1033	Childhood Leukemia. <b>2011</b> ,		6
1032	Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. <b>2011</b> , 25, 1135-61, vii		74
1031	Cytoplasmic nucleophosmin (cNPM) in acute myeloid leukaemia: Relation to disease characteristics Available online 26 August 2011 View all notes Peer review under responsibility of Alexandria University Faculty of Medicine View all notes. <b>2011</b> , 47, 225-235		
1030	Genomic profiling in high hyperdiploid acute myeloid leukemia: a retrospective study of 19 cases. <b>2011</b> , 204, 516-21		13
1029	Serine protease (TPS): A diagnostic and prognostic marker in pediatric patients with acute non-lymphoblastic leukemia. <b>2011</b> , 12, 165-170		
1028	Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. <b>2011</b> , 17, 356-64		47
1027	One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. <b>2011</b> , 17, 640-8		44
1026	Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. <b>2011</b> , 17, 1450-1459.e1		39
1025	Ocular myeloid sarcoma in a 10-year-old child. <b>2011</b> , 15, 504-5		6

1024	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. <b>2011</b> , 29, 2889-96		306
1023	Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. <b>2011</b> , 2, 658-68		59
1022	Chromosome abnormalities of hematologic malignancies. 185-201		
1021	Acute myeloid leukemia: update in diagnosis and treatment in Brazil. <b>2011</b> , 9, 179-83		1
1020	Pediatric Acute Myeloid Leukemia. <b>2011</b> ,		
1019	Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype. <b>2011</b> , 6, e20607		2
1018	RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. <b>2011</b> , 40, 627-33		17
1017	Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia. <b>2011</b> , 33, 281-8		10
1016	Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good prognosis in childhood acute leukemia. <b>2011</b> , 33, e143-8		2
1015	Hematogones: a new prognostic factor for acute myeloblastic leukemia. <i>Blood</i> , <b>2011</b> , 117, 1315-8	2.2	26
1014	Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. <i>Blood</i> , <b>2011</b> , 118, 1472-80	2.2	106
1013	MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. <i>Blood</i> , <b>2011</b> , 118, 2857-67	2.2	74
1012	High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). <i>Blood</i> , <b>2011</b> , 117, 928-35	2.2	15
1011	Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. <i>Blood</i> , <b>2011</b> , 117, 4552-60	2.2	167
1010	Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. <i>Blood</i> , <b>2011</b> , 118, 679-85	2.2	59
1009	Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis. <i>Blood</i> , <b>2011</b> , 117, 4881-4	2.2	7
1008	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. <i>Blood</i> , <b>2011</b> , 118, 409-12	2.2	200
1007	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. <i>Blood</i> , <b>2011</b> , 118, 1490-4	2.2	86

1006	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. <i>Blood</i> , <b>2011</b> , 118, 1754-62	2.2	42
1005	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). <i>Blood</i> , <b>2011</b> , 118, 5409-15	2.2	46
1004	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. <b>2011</b> , 96, 972-9		49
1003	Hypomethylating agents for adult patients with acute myeloid leukaemia. <b>2011</b> ,		
1002	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. <b>2011</b> , 96, 1375-9		20
1001	Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. <b>2011</b> , 96, 174-6		12
1000	Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. <b>2011</b> , 96, 221-30		73
999	Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <b>2011</b> , 96, 631-2		10
998	Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. <b>2011</b> , 96, 1310-7		52
997	Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. <b>2011</b> , 341, 404-8		9
996	Clinical results and issues of acute myeloid leukemia in elderly patients aged 75 years and older. <b>2011</b> , 11, 290-6		4
995	Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. <b>2011</b> , 102, 1358-65		4
994	Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols. <b>2011</b> , 155, 235-43		26
993	Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. <b>2011</b> , 155, 366-76		144
992	Cell lineage and cell death: <i>Caenorhabditis elegans</i> and cancer research. <b>2011</b> , 11, 50-8		20
991	Modulation of activated oncogene c-kit expression with RNA-interference. <b>2011</b> , 45, 950-958		8
990	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <b>2011</b> , 25, 75-81		39
989	The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. <b>2011</b> , 25, 246-53		113



988	Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. <b>2011</b> , 25, 1423-32	44
987	A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. <b>2011</b> , 25, 945-52	27
986	Targeting AML through DR4 with a novel variant of rhTRAIL. <b>2011</b> , 15, 2216-31	17
985	Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia. <b>2011</b> , 86, 237-45	3
984	Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?. <b>2011</b> , 38, 196-214	19
983	Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. <b>2011</b> , 80, 331-46	19
982	A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. <b>2011</b> , 39, 87-94	6
981	Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. <b>2011</b> , 39, 473-485.e4	25
980	Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. <b>2011</b> , 82, 1457-66	22
979	Unfavorable-risk cytogenetics in acute myeloid leukemia. <b>2011</b> , 4, 173-84	14
978	A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics. <b>2011</b> , 135, 921-8	26
977	Pathogenesis and consequences of uniparental disomy in cancer. <b>2011</b> , 17, 3913-23	71
976	ACUTE LEUKEMIAS XIII. <b>2011</b> , 90, 25-76	
975	A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy. <b>2011</b> , 90, 1283-91	2
974	Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. <b>2011</b> , 28, 544-51	13
973	Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts. <b>2011</b> , 94, 81-89	8
972	Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. <b>2011</b> , 2, 389-99	36
971	Redefining transplant in acute leukemia. <b>2011</b> , 12, 312-28	3

970	Who should be transplanted in first remission of acute myeloid leukaemia?. <b>2011</b> , 12, 329-40	3
969	Updates in cytogenetics and molecular markers in MDS. <b>2011</b> , 6, 126-35	35
968	Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia. <b>2011</b> , 56, 294-7	9
967	Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. <b>2011</b> , 57, 684-7	14
966	Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. <b>2011</b> , 86, 2-11	37
965	Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. <b>2011</b> , 86, 353-6	12
964	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. <b>2011</b> , 50, 51-8	6
963	Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. <b>2011</b> , 117, 1463-9	62
962	Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. <b>2011</b> , 117, 2156-62	19
961	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?. <b>2011</b> , 117, 3293-304	42
960	Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. <b>2011</b> , 128, 233-8	34
959	Independent prognostic variables in acute myeloid leukaemia. <b>2011</b> , 25, 39-51	80
958	Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. <b>2011</b> , 35, 516-21	12
957	RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFMYH11(+) acute myeloid leukemia. <b>2011</b> , 35, 1020-6	16
956	Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival—a retrospective study of 42 adult cases. <b>2011</b> , 35, 1027-31	4
955	FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. <b>2011</b> , 1, e42	6
954	Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. <b>2011</b> , 96, 632-4	25
953	Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia. <b>2011</b> , 52, 2031-5	1

952	Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. <b>2011</b> , 24, 375-83	79
951	Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. <b>2011</b> , 29, 4702-8	26
950	Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. <b>2011</b> , 22, 696-704	30
949	Core-binding factor acute myeloid leukemia. <b>2011</b> , 135, 1504-9	35
948	IDH1 and IDH2 mutations in pediatric acute leukemia. <b>2011</b> , 25, 1570-7	62
947	Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. <b>2011</b> , 29, 2507-13	54
946	Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. <b>2011</b> , 16, 197-206	24
945	Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. <b>2011</b> , 108, 5009-14	191
944	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. <b>2011</b> , 29, 682-9	47
943	Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature. <b>2011</b> , 125, 237-41	5
942	Cytogenetic abnormalities in myelodysplastic syndrome: an overview. <b>2011</b> , 16, 131-8	22
941	Pediatric acute leukemia therapies informed by molecular analysis of high-risk disease. <b>2011</b> , 2011, 366-73	8
940	New considerations in the design of clinical trials for the treatment of acute leukemia. <b>2011</b> , 1, 509-517	7
939	Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. <b>2011</b> , 11, 20-30	10
938	Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. <b>2011</b> , 29, 369-77	485
937	Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation. <b>2011</b> , 48, 182-97	22
936	Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. <b>2011</b> , 25, 808-13	105
935	Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. <b>2011</b> , 29, 2758-65	177

934	Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. <b>2011</b> , 96, 231-7	81
933	Complexity on Acute Myeloid Leukemia mRNA Transcript Variant. <b>2011</b> , 2011, 1-16	10
932	Pediatric acute myeloid leukemia--is there a scope for change in the developing world?. <b>2011</b> , 28, 253-6	
931	The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). <b>2012</b> , 4, 1161-79	4
930	Cytogenetics findings in a histiocytic sarcoma case. <b>2012</b> , 2012, 428279	5
929	Microarrays and cancer diagnosis. <b>2012</b> , 8, 3-10	12
928	Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. <b>2012</b> , 47, 1513-9	22
927	Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. <b>2012</b> , 21, 225-33	19
926	Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. <b>2012</b> , 13, 307-13	16
925	DNA copy number changes and immunophenotype pattern in karyotypically normal acute myeloid leukemia patients from an Indian population. <b>2012</b> , 16, 265-70	2
924	Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. <b>2012</b> , 53, 103-9	16
923	Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. <b>2012</b> , 26, 822-4	16
922	Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. <b>2012</b> , 26, 2469-73	23
921	Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. <b>2012</b> , 26, 461-4	17
920	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. <b>2012</b> , 12, 111-8	31
919	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. <b>2012</b> , 26, 289-95	28
918	Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. <b>2012</b> , 47, 196-202	10
917	Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. <b>2012</b> , 128, 203-12	9

916	Acute myeloid leukemia: focus on novel therapeutic strategies. <b>2012</b> , 6, 205-17		23
915	Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. <b>2012</b> , 57		
914	Trisomy 11 as an additional chromosome alteration in a child with acute promyelocytic leukemia with poor prognosis. <b>2012</b> , 2012, 659016		4
913	Rearrangement of the myeloid/lymphoid leukemia gene in therapy-related myelodysplastic syndrome in patients previously treated with agents targeting DNA topoisomerase II. <b>2012</b> , 83, 128-34		9
912	NCCN Clinical Practice Guidelines Acute myeloid leukemia. <b>2012</b> , 10, 984-1021		194
911	Diagnosis and classification. 21-48		1
910	Cytogenetics of acute leukemias. 135-167		
909	Acute myeloid leukemia. 395-420		1
908	Myelodysplastic syndrome. 429-443		
907	Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. <b>2012</b> , 97, 915-8		24
906	Acute myeloid leukemia in the elderly. <b>2012</b> , 1, 57-69		1
905	A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 196-205	2.2	23
904	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 3571-7	2.2	174
903	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 5980-8	2.2	61
902	Interphase Chromosome Flow-FISH. <i>Blood</i> , <b>2012</b> , 120, e54-9	2.2	3
901	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 120, 4840-5	2.2	169
900	Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients. <b>2012</b> , 16, 707-15		5
899	DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. <b>2012</b> , 159, 182-90		18

898	Childhood acute myeloid leukaemia. <b>2012</b> , 159, 259-76		59
897	The changing paradigm of prognostic factors in acute myeloid leukaemia. <b>2012</b> , 25, 419-25		21
896	Prognostic significance of FLT3 internal tandem duplication in Egyptian acute myeloid leukemia and normal cytogenetics. <b>2012</b> , 21, 1029-1035		2
895	Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. <b>2012</b> , 45, 1362-7		9
894	Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. <b>2012</b> , 30, 3924-31		305
893	Recent advances in the understanding and treatment of pediatric leukemias. <b>2012</b> , 59, 329-58		11
892	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). <b>2012</b> , 53, 445-50		16
891	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <b>2012</b> , 53, 96-102		17
890	A novel hierarchical prognostic model of AML solely based on molecular mutations. <i>Blood</i> , <b>2012</b> , 120, 2963-72	2.2	189
889	Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. <i>Blood</i> , <b>2012</b> , 119, 34-43	2.2	388
888	Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. <b>2012</b> , 53, 660-4		7
887	Combination of cytogenetic analysis and molecular screening in patients with de novo acute myeloid leukemia. <b>2012</b> , 32, 501-510		1
886	Use of rHuG-CSF for the Treatment of Myeloid Leukemia and in Targeting Leukemia Stem Cells. <b>2012</b> , 169-182		
885	Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. <b>2012</b> , 4, 127ra38		64
884	Erythroid proliferations in myeloid neoplasms. <b>2012</b> , 43, 153-64		23
883	Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. <b>2012</b> , 18, 280-8		64
882	Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation. <b>2012</b> , 18, 754-62		15
881	Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. <b>2012</b> , 18, 473-80		17

880	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , <b>2012</b> , 120, 3187-205	2.2	359
879	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. <b>2012</b> , 30, 4515-23		310
878	A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. <b>2012</b> , 87, 961-8		7
877	Whole chromosome aneuploidy: big mutations drive adaptation by phenotypic leap. <b>2012</b> , 34, 893-900		50
876	Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF). <b>2012</b> , 12, 25		4
875	Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. <b>2012</b> , 47, 46-53		26
874	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. <b>2012</b> , 26, 1313-20		78
873	Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. <b>2012</b> , 31, 1533-45		43
872	Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia. <b>2012</b> , 13, 2171-87		4
871	Chromosomal aberrations and fusion genes in myeloid malignancies. <b>2012</b> , 5, 381-93		10
870	Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. <b>2012</b> , 5, 17-26		13
869	Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia. <b>2012</b> , 49, 107-13		10
868	Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. <b>2012</b> , 66, 578-82		8
867	Acute myeloid leukemia presenting in a mother and daughter pair with the identical acquired karyotypic abnormality consisting of inversion 3q21q26 and monosomy 7: a review of possible mechanisms. <b>2012</b> , 205, 599-602		5
866	Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. <b>2012</b> , 12, 274-9		13
865	Clinical cytogenetics in pediatric acute leukemia: an update. <b>2012</b> , 12, 230-7		16
864	Incidence, survival and prevalence of myeloid malignancies in Europe. <b>2012</b> , 48, 3257-66		132
863	Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. <b>2012</b> , 36, 1283-9		77



862	Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?. <b>2012</b> , 36, 1547-51	18
861	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. <b>2012</b> , 53, 1352-9	66
860	Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML. <b>2012</b> , 29, 2083-7	4
859	Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. <b>2012</b> , 29, 3547-56	8
858	Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. <b>2012</b> , 96, 485-91	5
857	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. <b>2012</b> , 96, 342-9	5
856	Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. <b>2012</b> , 96, 171-7	20
855	Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. <b>2012</b> , 53, 289-94	10
854	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. <b>2012</b> , 26, 2176-85	98
853	Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. <b>2012</b> , 7, e43185	11
852	Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. <b>2012</b> , 32, 153-7	7
851	Acute myeloid leukaemia associated to chromosome 6: Clinical and phenotypical implications in two pediatric patients with chromosome trisomy and translocation. <b>2012</b> , 4, 1-9	
850	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. <b>2012</b> , 97, 235-40	12
849	Prognosis and Survival in Acute Myelogenous Leukemia. <b>2012</b> ,	2
848	Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant. <b>2012</b> , 53, 530-6	11
847	The detection of KIT mutations in acute myeloid leukemia. <b>2012</b> , 10, 286-91	1
846	Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples. <b>2012</b> , 5, 6	5
845	Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. <i>Blood</i> , <b>2012</b> , 119, 206-16	2.2 78

844	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. <b>2012</b> , 29, 2348-58		3
843	Genetic and epigenetic similarities and differences between childhood and adult AML. <b>2012</b> , 58, 525-31		25
842	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 332-41	2.2	209
841	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 5824-31	2.2	193
840	Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. <b>2012</b> , 97, 241-5		18
839	Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. <b>2012</b> , 91, 671-677		15
838	Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway. <b>2012</b> , 91, 645-669		31
837	Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. <b>2012</b> , 87, 659-62		55
836	Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <b>2012</b> , 87, 1047-51		21
835	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <b>2012</b> , 118, 2411-9		23
834	Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <b>2012</b> , 118, 2420-3		6
833	De novo acute myeloid leukemia risk factors: a Texas case-control study. <b>2012</b> , 118, 4589-96		31
832	Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. <b>2012</b> , 118, 5278-82		38
831	Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. <b>2012</b> , 81, 776-84		22
830	Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. <b>2012</b> , 82, 123-31		9
829	Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. <b>2012</b> , 82, 158-72		24
828	VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. <b>2012</b> , 55, 725-34		14
827	Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. <b>2012</b> , 30, 1343-9		79

826	Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. <i>Blood</i> , <b>2012</b> , 119, 2122-5	2.2	59
825	RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. <b>2012</b> , 95, 509-15		25
824	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. <b>2012</b> , 96, 84-93		27
823	Treatment outcome in AML: a single-centre experience in an unselected patient cohort. <b>2012</b> , 5, 134-140		1
822	Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. <b>2012</b> , 31, 991-7		35
821	Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: association with CD34(+) mobilization and with disease-free survival. <b>2012</b> , 40, 35-47.e2		3
820	Role of autophagy in the progression and suppression of leukemias. <b>2012</b> , 81, 275-85		20
819	Single-nucleotide polymorphism array karyotyping in clinical practice: where, when, and how?. <b>2012</b> , 39, 13-25		30
818	Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response. <b>2012</b> , 111, 317-24		8
817	Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations. <b>2012</b> , 88, 136-43		12
816	Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. <b>2012</b> , 88, 128-35		55
815	Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. <b>2012</b> , 36, 186-91		16
814	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. <b>2012</b> , 36, 316-23		47
813	Clinical profile and outcome of patients of acute myeloid leukemia with high hyperdiploidy. <b>2012</b> , 36, e60-1		
812	Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia. <b>2012</b> , 103, 1513-7		27
811	Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. <b>2012</b> , 118, 112-7		51
810	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <b>2012</b> , 118, 410-7		19
809	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. <b>2012</b> , 118, 418-27		21

808	ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. <b>2012</b> , 87, 116-9	12
807	Cyclic thrombocytopenia associated with marked rebound thrombocytosis and fluctuating levels of endogenous thrombopoietin and reticulated platelets: a case report. <b>2012</b> , 87, 120-2	6
806	Is HbA2 level a reliable diagnostic measurement for $\beta$ -thalassemia trait in people with iron deficiency?. <b>2012</b> , 87, 114-6	22
805	Unintended benefit of anabolic steroid use in hemophilia B leiden. <b>2012</b> , 87, 122-3	4
804	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. <b>2012</b> , 87, 37-41	20
803	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. <b>2012</b> , 87, 129-30	1
802	Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. <b>2012</b> , 87, 123-5	35
801	Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. <b>2012</b> , 87, 69-77	18
800	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. <b>2012</b> , 87, 127-9	24
799	Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia. <b>2012</b> , 87, 126-7	2
798	Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association. <b>2012</b> , 87, 62-5	31
797	A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. <b>2012</b> , 87, 111-4	18
796	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. <b>2012</b> , 91, 19-25	5
795	Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. <b>2012</b> , 30, 468-79	5
794	Clonal evolution of acute leukemia genomes. <b>2013</b> , 32, 135-40	88
793	A unifying diagnosis for pancytopenia, fever, hypoglycemia, and lactic acidosis. <b>2013</b> , 88, 78-81	2
792	A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints. <b>2013</b> , 6, 18	3
791	Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. <b>2013</b> , 6, 32	52

790	Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. <b>2013</b> , 34, 629-36	19
789	Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia. <b>2013</b> , 15, 678-86	8
788	Leukemias, Lymphomas, and Other Related Disorders. <b>2013</b> , 1-44	1
787	Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. <b>2013</b> , 97, 773-81	3
786	Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies. <b>2013</b> , 30, 373-81	9
785	Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. <b>2013</b> , 37, 1606-11	26
784	The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. <b>2013</b> , 92, 1063-9	17
783	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. <b>2013</b> , 92, 315-23	40
782	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. <b>2013</b> , 37, 769-76	8
781	Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array. <b>2013</b> , 17, 395-400	7
780	Monosomal karyotype in acute myeloid leukemia defines a distinct subgroup within the adverse cytogenetic risk category. <b>2013</b> , 206, 32-6	13
779	Acute leukaemia. <b>2013</b> , 41, 269-274	0
778	Prognostic implications of CD14 positivity in acute myeloid leukemia arising from myelodysplastic syndrome. <b>2013</b> , 97, 246-55	5
777	Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. <b>2013</b> , 37, 287-92	33
776	Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. <b>2013</b> , 13, 435-40	23
775	Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. <b>2013</b> , 27, 879-88	39
774	Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <b>2013</b> , 31, 3360-8	247
773	Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis. <b>2013</b> , 27, 2149-56	11

772	Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia. <b>2013</b> , 19, 958-66	19
771	Animal models of leukemia: any closer to the real thing?. <b>2013</b> , 32, 63-76	33
770	WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. <b>2013</b> , 98, 437-45	13
769	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. <b>2013</b> , 13, 364	38
768	Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. <b>2013</b> , 37, 1477-81	20
767	Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management. <b>2013</b> , 160, 303-20	44
766	Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. <b>2013</b> , 27, 1044-52	67
765	"It's effective therapy, stupid!". <b>2013</b> , 37, 1434-5	1
764	Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. <b>2013</b> , 13, 153-8	10
763	Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. <b>2013</b> , 37, 1451-6	12
762	[Spontaneous remission of bone marrow aplasia associated with chromosome 8 trisomy, with subsequent evolution to acute monoblastic leukemia and recurrence of the clonal abnormality]. <b>2013</b> , 141, 42-3	
761	Providing personalized prognostic information for adult leukemia survivors. <b>2013</b> , 19, 1600-7	12
760	Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. <b>2013</b> , 13 Suppl 2, S276-81	4
759	Invasive infections caused by <i>Saprochaete capitata</i> in patients with haematological malignancies: report of five cases and review of the antifungal therapy. <b>2013</b> , 30, 248-55	43
758	Ostra biańczka szpikowa u osób w wieku podeszłym. <b>2013</b> , 44, 75-84	1
757	CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). <b>2013</b> , 37, 1021-6	30
756	High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. <b>2013</b> , 37, 556-60	6
755	[Prediction of frailty fractures or prediction of densitometric osteoporosis. That is the question!]. <b>2013</b> , 141, 43-4	3

754	CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. <b>2013</b> , 37, 1488-94	10
753	Mutational landscape of AML with normal cytogenetics: biological and clinical implications. <b>2013</b> , 27, 13-22	74
752	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. <b>2013</b> , 52, 385-401	13
751	Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation. <b>2013</b> , 160, 80-6	7
750	Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. <b>2013</b> , 160, 188-98	35
749	Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. <b>2013</b> , 213-239	
748	Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. <b>2013</b> , 355-373	1
747	Analyzing acute leukemia patients with complex MLL rearrangements by a sequential LDI-PCR approach. <b>2013</b> , 338, 249-54	4
746	Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. <b>2013</b> , 6, rs6	187
745	Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?. <b>2013</b> , 8, 109-15	8
744	Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. <b>2013</b> , 43, 903-11	12
743	Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. <b>2013</b> , 999, 105-21	1
742	Establishment of xenotransplantation model of human CN-AML with FLT3-ITD (mut) /NPM1 (-) in NOD/SCID mice. <b>2013</b> , 33, 329-334	1
741	The Cytogenetics of Hematologic Neoplasms. <b>2013</b> , 309-370	
740	Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. <b>2013</b> , 48, 1065-9	10
739	Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. <b>2013</b> , 19, 283-90	24
738	Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. <b>2013</b> , 19, 607-15	22
737	Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. <b>2013</b> , 11, 275-86	90



736	Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta. <b>2013</b> , 88, 594-600	19
735	Decitabine for the treatment of acute myeloid leukemia. <b>2013</b> , 1, 661-673	3
734	Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. <b>2013</b> , 54, 541-6	24
733	Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. <b>2013</b> , 54, 528-34	9
732	Medical emergency team involvement in patients hospitalized with acute myeloid leukemia. <b>2013</b> , 54, 2236-42	6
731	Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature. <b>2013</b> , 30, 400-4	4
730	The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia. <b>2013</b> , 43, 1047-51	3
729	Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. <b>2013</b> , 48, 1185-91	6
728	The thorny issue of relapsed acute myeloid leukemia. <b>2013</b> , 20, 100-6	6
727	High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. <b>2013</b> , 31, 3889-97	301
726	Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia. <b>2013</b> , 21, 205-11	3
725	Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). <b>2013</b> , 140, 525-35	26
724	Treatment of acute myeloid leukaemia. <b>2013</b> , 13 Suppl 6, s58-61	1
723	Age-specific distributions of cytogenetic subgroups of acute myeloid leukemia: data analysis in a Chinese population. <b>2013</b> , 129, 175-81	4
722	Translocation t(5;18)(q35;q21) as a rare nonrandom abnormality in acute myeloid leukemia. <b>2013</b> , 139, 289-94	3
721	Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. <b>2013</b> , 160, 861-3	5
720	Update on optimal management of acute myeloid leukemia. <b>2013</b> , 7, 181-97	10
719	Single nucleotide polymorphism array-based karyotyping in acute myeloid leukemia or myelodysplastic syndrome with trisomy 8 as the sole chromosomal abnormality. <b>2013</b> , 129, 154-8	5

718	Diagnostic complexities of eosinophilia. <b>2013</b> , 137, 259-69		32
717	Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase. <b>2013</b> , 88, 1001-6		25
716	Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. <b>2013</b> , 48, 56-62		13
715	Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. <b>2013</b> , 163, 62-71		5
714	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. <b>2013</b> , 163, 130-2		
713	GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. <b>2013</b> , 27, 482-5		74
712	High-dose cytarabine (24 g/m <sup>2</sup> ) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <b>2013</b> , 43, 294-7		9
711	B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22). <b>2013</b> , 140, 355-62		7
710	Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays. <b>2013</b> , 17, 295-300		4
709	BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia. <b>2013</b> , 60, E63-6		13
708	Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. <b>2013</b> , 27, 750-4		34
707	Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. <b>2013</b> , 98, 1525-31		22
706	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , <b>2013</b> , 121, 4056-62	2.2	206
705	NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population. <b>2013</b> , 35, e100-8		5
704	Core binding factor acute myeloid leukaemia and c-KIT mutations. <b>2013</b> , 29, 1867-72		23
703	Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. <b>2013</b> , 98, 230-8		52
702	Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 12, 5414-23		5
701	Expression and prognostic significance of hsa-miR-142-3p in acute leukemias. <b>2013</b> , 60, 432-8		22

700	Exploring the acute myeloid leukaemias. <b>2013</b> , 3, 497-501	
699	Utility of a multiplex reverse transcriptase-polymerase chain reaction assay (HemaVision) in the evaluation of genetic abnormalities in Korean children with acute leukemia: a single institution study. <b>2013</b> , 56, 247-53	6
698	Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. <b>2013</b> , 48, 24-30	10
697	The molecular basis of acute myeloid leukemia. 751-768	
696	Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. <b>2014</b> , 9, e93353	34
695	The corepressor Tle4 is a novel regulator of murine hematopoiesis and bone development. <b>2014</b> , 9, e105557	18
694	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation. <b>2014</b> , 27, 299-304	1
693	. <b>2014</b> ,	18
692	Intermediate-risk acute myeloid leukemia therapy: current and future. <b>2014</b> , 2014, 34-43	2
691	Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Soci�t� Fran�aise de Greffe de Moelle et de Therapie Cellulaire. <b>2014</b> , 49, 382-8	17
690	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. <i>Blood</i> , <b>2014</b> , 124, 1312-9	2.2 49
689	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran�aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <b>2014</b> , 49, 756-60	27
688	Daunorubicin for the treatment of acute myeloid leukemia. <b>2014</b> , 2, 1075-1087	
687	Intermediate-risk acute myeloid leukemia therapy: current and future. <b>2014</b> , 2014, 34-43	22
686	Distribution of Different PML/RAR�bcr Isoforms in Indian Acute Promyelocytic Leukemia (APL) Patients and Clinicohematological Correlation. <b>2014</b> , 6, e2014004	6
685	acute myeloid leukemia subtype-M4 with initial trisomy 8 and later acquired t(3;12)(q26;p12) leading to ETV6/MDS1/EVI1 fusion transcript expression: A case report. <b>2014</b> , 7, 787-790	4
684	Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. <b>2014</b> , 19, 352-60	19
683	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. <b>2014</b> , 99, 836-47	123

682	MLL-SEPT5 fusion transcript in infant acute myeloid leukemia with t(11;22)(q23;q11). <b>2014</b> , 55, 662-7	8
681	Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. <b>2014</b> , 38, 1425-9	12
680	DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia. <b>2014</b> , 5, 187-96	8
679	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of patients with mixed-lineage-leukemia-rearranged acute leukemia: Results from a prospective, multi-center study. <b>2014</b> , 89, 130-6	12
678	[Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia]. <b>2014</b> , 101, 856-65	1
677	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. <b>2014</b> , 2, 18	22
676	CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia. <b>2014</b> , 7, 66	9
675	Quantitative assessment of BAX transcript and flow cytometric expression in acute myeloid leukemia: a prospective study. <b>2014</b> , 19, 404-11	1
674	Genetic mutations in acute myeloid leukemia that influence clinical decisions. <b>2014</b> , 21, 87-94	8
673	NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia. <b>2014</b> , 24, 436-41	8
672	A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic VβVα T cells. <b>2014</b> , 37, 321-30	16
671	Identifying differentially expressed genes for ordinal phenotypes. <b>2014</b> ,	
670	The epigenetic landscape of acute myeloid leukemia. <b>2014</b> , 2014, 103175	61
669	Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort. <b>2014</b> , 36, 656-64	11
668	Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. <b>2014</b> , 61, 269-75	22
667	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. <b>2014</b> , 28, 78-87	226
666	ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. <b>2014</b> , 55, 1326-31	12
665	Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia-rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 20, 929-36	18

664	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. <b>2014</b> , 55, 855-62	13
663	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. <b>2014</b> , 55, 979-87	29
662	Glutathione S-transferase genotypes and numerical chromosomal aberrations in myeloid neoplasms. <b>2014</b> , 23, 1023-1029	1
661	Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome. <b>2014</b> , 93, 957-63	10
660	Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. <b>2014</b> , 100, 27-37	43
659	Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. <b>2014</b> , 164, 384-95	41
658	Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. <b>2014</b> , 165, 147-51	4
657	Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. <b>2014</b> , 20, 387-93	12
656	Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. <b>2014</b> , 14, 93-7	13
655	A critical review of which children with acute myeloid leukaemia need stem cell procedures. <b>2014</b> , 166, 23-33	51
654	Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia. <b>2014</b> , 41, 400-7	3
653	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. <b>2014</b> , 38, 649-59	35
652	Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. <b>2014</b> , 28, 50-8	68
651	Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. <b>2014</b> , 28, 321-8	26
650	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. <b>2014</b> , 20, 46-52	72
649	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , <b>2014</b> , 123, 914-20	2.2 129
648	Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status. <b>2014</b> , 14, 509-13	2
647	Relative receptor tyrosine kinases and anti-apoptotic transcripts hold potential for predicting inferior outcome in adult acute myeloid leukemia: a prospective pilot study. <b>2014</b> , 14, 501-508.e2	

646	Acute myeloid leukemia in adolescents and young adults: challenging aspects. <b>2014</b> , 132, 292-7	22
645	IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. <b>2014</b> , 92, 471-7	31
644	Concise review: Leukemia stem cells in personalized medicine. <b>2014</b> , 32, 844-51	40
643	Clofarabine/cyclophosphamide for debulking before stem cell transplantation. <b>2014</b> , 44, 775-83	3
642	Acute Myeloid Leukemia. <b>2014</b> , 283-300	2
641	FLT3-ITD mutation in relation to FLT3 expression in pediatric AML: a prospective study from India. <b>2014</b> , 31, 131-7	2
640	Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. <b>2014</b> , 49, 1466-74	21
639	A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. <b>2014</b> , 49, 955-60	2
638	Evolving treatment strategies in patients with high-risk acute myeloid leukemia. <b>2014</b> , 55, 2438-48	8
637	Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. <b>2014</b> , 89, 1121-31	32
636	The genomic and epigenomic landscapes of AML. <b>2014</b> , 51, 259-72	11
635	Mutation position within evolutionary subclonal architecture in AML. <b>2014</b> , 51, 273-81	14
634	Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. <b>2014</b> , 49, 1029-35	27
633	FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia. <b>2014</b> , 93, 577-93	14
632	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. <b>2014</b> , 93, 1825-38	73
631	The use of molecular genetics to refine prognosis in acute myeloid leukemia. <b>2014</b> , 9, 148-57	9
630	Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. <b>2014</b> , 16, 213-27	17
629	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. <b>2014</b> , 99, 1456-64	22

628	Bioluminescence: Fundamentals and Applications in Biotechnology - Volume 2. <b>2014</b> ,	3
627	Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. <b>2014</b> , 38, 443-6	29
626	Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study. <b>2014</b> , 53, 667-75	20
625	Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?. <b>2014</b> , 20, 80-8	7
624	Długostrwał odpowiedŃa leczenie azacytydynŃ pacjentki z ostrŃbiaŃczkŃszpikowŃz niekorzystnym profilem cytogenetycznym Ń prezentacja przypadku. <b>2014</b> , 45, 93-96	
623	Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. <b>2014</b> , 38, 907-12	3
622	Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. <b>2014</b> , 53, 144-8	10
621	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. <b>2014</b> , 6, 69-81	24
620	Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers. <b>2014</b> , 12, 527-34	4
619	Acute myeloid leukemia in the pregnant patient. <b>2015</b> ,	4
618	Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia. <b>2015</b> , 113, 201-8	8
617	Akute myeloische LeukŃmie. <b>2015</b> , 10, 42-51	
616	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. <b>2015</b> , 90, 1065-70	16
615	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology. <b>2015</b> , 22, 158-66	12
614	The applicability of the WHO classification in paediatric AML. A NOPHO-AML study. <b>2015</b> , 169, 859-67	13
613	Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. <b>2015</b> , 11, 242-52	18
612	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <b>2015</b> , 90, 769-73	20
611	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study. <b>2015</b> , 90, 904-9	3



610	Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation. <b>2015</b> , 99, 1065-71	17
609	The Impact of Molecular Genetic in Acute Myeloid Leukemias. <b>2015</b> , 06,	
608	Volasertib for AML: clinical use and patient consideration. <b>2015</b> , 8, 1761-71	10
607	Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. <b>2015</b> , 6, 30212-21	29
606	Characterization of Leukemia-Inducing Genes Using a Proto-Oncogene/Homeobox Gene Retroviral Human cDNA Library in a Mouse In Vivo Model. <b>2015</b> , 10, e0143240	2
605	Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia. <b>2016</b> , 16, 128-35	16
604	Transcriptome Profiling of Pediatric Core Binding Factor AML. <b>2015</b> , 10, e0138782	11
603	Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients. <b>2016</b> , 17, 52-70	20
602	Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients. <b>2015</b> , 2015, 723682	7
601	Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?. <b>2015</b> , 22, 123-31	3
600	AML1/ETO cooperates with HIF1 $\alpha$ to promote leukemogenesis through DNMT3a transactivation. <b>2015</b> , 29, 1730-40	50
599	Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function. <b>2015</b> , 39, 689-95	6
598	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <b>2015</b> , 28, 965-76	20
597	A randomized comparison of daunorubicin 90 mg/m <sup>2</sup> vs 60 mg/m <sup>2</sup> in AML induction: results from the UK NCRI AML17 trial in 1206 patients. <i>Blood</i> , <b>2015</b> , 125, 3878-85	2.2 176
596	Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22). <b>2015</b> , 102, 205-10	
595	The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients. <b>2015</b> , 39, 667-71	5
594	Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21) translocation?. <b>2015</b> , 133, 264-5	
593	INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. <b>2015</b> , 29, 1485-95	34

592	Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. <b>2015</b> , 94, 1337-45	3
591	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <b>2015</b> , 21, 1405-1412	20
590	Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <b>2015</b> , 33, 4247-58	56
589	Is amplification of c-MYC, MLL and RUNX1 genes in AML and MDS patients with trisomy 8, 11 and 21 a factor for a clonal evolution in the karyotype?. <b>2015</b> , 49, 165-172	2
588	Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. <b>2015</b> , 10, 122	3
587	Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance. <b>2015</b> , 275-317	2
586	Different aspects of stem cell procedures in children with poor responding AML: when is HSCT the best answer?. <b>2015</b> , 4, 67-75	
585	Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. <b>2015</b> , 8, 106-14	4
584	Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. <b>2015</b> , 34, 488-94	4
583	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. <b>2015</b> , 8, 43-56	21
582	Hierarchy in gene expression is predictive of risk, progression, and outcome in adult acute myeloid leukemia. <b>2015</b> , 12, 016016	4
581	-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity. <b>2015</b> , 34, 2413-25	36
580	Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná <b>2015</b> , 37, 21-7	16
579	Acute myeloid leukemia in the pregnant patient. <b>2015</b> , 95, 124-36	12
578	One day at a time: improving the patient experience during and after intensive chemotherapy for younger and older AML patients. <b>2015</b> , 39, 192-7	8
577	Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. <b>2015</b> , 29, 1243-52	26
576	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. <b>2015</b> , 21, 713-9	26
575	Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. <b>2015</b> , 94, 413-8	17

574	Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. <b>2015</b> , 39, 204-10	11
573	Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials. <b>2015</b> , 5, 89-110	1
572	Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. <b>2015</b> , 71, 293-302	15
571	Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. <b>2015</b> , 5, 988-1003	69
570	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). <b>2015</b> , 29, 2375-81	29
569	A novel approach to quantitating leukemia fusion transcripts by qRT-PCR without the need for standard curves. <b>2015</b> , 99, 104-8	4
568	Differential profile of PIP4K2A expression in hematological malignancies. <b>2015</b> , 55, 228-35	5
567	A multigene array for measurable residual disease detection in AML patients undergoing SCT. <b>2015</b> , 50, 642-51	27
566	A novel clonal t(1;4)(p36.1;q31) translocation in acute promyelocytic leukaemia. <b>2015</b> , 68, 391-3	
565	Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. <b>2015</b> , 9, 1217-1220	3
564	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. <b>2015</b> , 15, 556-62	7
563	Tropical Hemato-Oncology. <b>2015</b> ,	2
562	Insights into cell ontogeny, age, and acute myeloid leukemia. <b>2015</b> , 43, 745-55	19
561	Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. <b>2015</b> , 52, 215-22	26
560	Molecular characterization and testing in acute myeloid leukemia. <b>2015</b> , 8, 177-189	1
559	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 126, 319-27	2.2 185
558	Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission. <b>2015</b> , 50, 907-13	20
557	Direct and indirect targeting of MYC to treat acute myeloid leukemia. <b>2015</b> , 76, 35-46	27

556	Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. <b>2015</b> , 94, 1485-92	11
555	Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. <b>2015</b> , 33, 1839-49	11
554	Approach to patients with primary refractory acute myeloid leukemia. <b>2015</b> , 22, 97-107	9
553	Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?. <b>2015</b> , 38, 159-64	25
552	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <b>2015</b> , 56, 3116-23	19
551	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. <b>2015</b> , 94, 1797-806	8
550	Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. <b>2015</b> , 28, 90-7	8
549	Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome. <b>2015</b> , 133, 183-92	3
548	Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. <b>2015</b> , 94, 419-23	12
547	Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. <b>2015</b> , 94, 439-48	29
546	The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. <b>2015</b> , 37 Suppl 1, 122-32	7
545	Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. <b>2015</b> , 195, 2580-90	49
544	Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. <b>2015</b> , 121, 2900-8	20
543	Acute Leukemia. <b>2015</b> , 279-289	
542	Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. <b>2015</b> , 16, 37	22
541	Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. <b>2015</b> , 32, 623-37	14
540	Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. <b>2015</b> , 60, 749-54	14
539	FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3. <b>2015</b> , 39, 1405-13	14

538	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <b>2015</b> , 39, 1367-74	35
537	Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. <b>2015</b> , 56, 1398-405	30
536	A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. <b>2015</b> , 29, 1478-84	25
535	Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21). <b>2015</b> , 133, 266-76	7
534	Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. <b>2015</b> , 35, 586-618	101
533	Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. <b>2015</b> , 28, 706-14	89
532	A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms. <b>2015</b> , 17, 76-84	26
531	Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia. <b>2015</b> , 56, 1874-7	3
530	High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia. <b>2015</b> , 54, 56-64	3
529	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. <b>2015</b> , 29, 51-7	55
528	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. <b>2015</b> , 1853, 14-26	58
527	WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. <b>2015</b> , 29, 660-7	49
526	Management of Acute Myeloid Leukemia in the Intensive Care Setting. <b>2015</b> , 30, 375-84	5
525	. <b>2016</b> ,	2
524	Comparable Outcome of Allogeneic versus Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Normal Karyotype and FLT3-ITD Negative. <b>2016</b> , 4,	
523	Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center. <b>2016</b> , 62, 641-646	2
522	Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. <b>2016</b> , 2016, 7625827	6
521	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. <b>2016</b> , 11, e0153016	9

520	Low dose cytarabine monotherapy for acute myeloid leukaemia. <b>2016</b> ,		
519	Multi-drug resistance protein 1 as prognostic biomarker in clinical practice for acute myeloid leukemia. <b>2016</b> , 38, e93-7		4
518	Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study. <b>2016</b> , 47, 172-9		8
517	Establishment of a prediction model of changing trends in cardiac hypertrophy disease based on microarray data screening. <b>2016</b> , 11, 1734-1740		3
516	Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. <b>2016</b> , 47, 149-60		12
515	A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. <b>2016</b> , 174, 700-10		36
514	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. <b>2016</b> , 97, 471-478		4
513	The prognostic value of hematogones in patients with acute myeloid leukemia. <b>2016</b> , 91, 566-70		6
512	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. <b>2016</b> , 91, 755-62		16
511	FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. <b>2016</b> , 96, 475-82		14
510	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). <b>2016</b> , 101, 1516-1523		10
509	Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPβ as a common target of TRIB1 and PML/RARA. <b>2016</b> , 101, 1228-1236		16
508	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. <i>Blood</i> , <b>2016</b> , 128, 2819-2823	2.2	19
507	Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. <b>2016</b> , 22, 1125-1132		16
506	Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. <b>2016</b> , 47, 47-53		7
505	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <b>2016</b> , 95, 625-35		11
504	EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements. <b>2016</b> , 291, 13591-607		8
503	The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <b>2016</b> , 21, 692-700		32

502	Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. <b>2016</b> , 45, 47-52		4
501	Etiology and Prevention of Acute Leukemias in Children. <b>2016</b> , 49-74		
500	Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. <b>2016</b> , 145, 214-225		32
499	Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. <b>2016</b> , 145, 538-51		18
498	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , <b>2016</b> , 127, 2742-50	2.2	97
497	Acute myeloid leukaemia. <b>2016</b> , 133-202		
496	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <b>2016</b> , 22, 1961-1967		25
495	Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report. <b>2016</b> , 10, 203		2
494	Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia. <b>2016</b> , 50, 57-62		6
493	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. <b>2016</b> , 175, 226-236		43
492	BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia. <b>2016</b> , 15, 2323-2333		9
491	Using Molecular Data in Allogeneic Hematopoietic Cell Transplantation Outcomes for Acute Myeloid Leukemia: Underestimating True Tumor Diversity?. <b>2016</b> , 22, 1911-1912		
490	Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China. <b>2016</b> , 136, 201-209		5
489	Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population. <b>2016</b> , 20, 696-701		11
488	ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. <b>2016</b> , 48, 16-9		0
487	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 35, 46		10
486	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <b>2016</b> , 374, 2209-2221		1999
485	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <b>2016</b> , 145, 769-77		29



484	Histamine H Receptor in Blood Cells: A Suitable Target for the Treatment of Acute Myeloid Leukemia. <b>2017</b> , 241, 141-160	9
483	Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?. <b>2016</b> , 47, 142-8	13
482	Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. <b>2016</b> , 16, 37	12
481	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study. <b>2016</b> , 173, 292-302	16
480	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <b>2016</b> , 22, 248-257	27
479	Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia. <b>2016</b> , 57, 2208-11	8
478	Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. <b>2015</b> , 108,	12
477	Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. <b>2016</b> , 30, 1485-92	79
476	Etiology of Acute Leukemias in Children. <b>2016</b> ,	1
475	Hypomethylating agents for adult patients with acute myeloid leukaemia. <b>2016</b> ,	
474	Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. <b>2016</b> , 22, 811-815	3
473	Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group. <b>2016</b> , 103, 416-22	3
472	Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. <b>2016</b> , 51, 1019-21	4
471	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <b>2016</b> , 40, 1-9	25
470	Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. <b>2016</b> , 57, 1560-6	10
469	Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. <b>2016</b> , 57, 1311-8	23
468	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. <b>2016</b> , 67, 59-72	32
467	Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). <b>2016</b> , 142, 305-15	15

466	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. <b>2016</b> , 30, 55-64	23
465	High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. <b>2016</b> , 57, 92-8	28
464	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. <b>2017</b> , 31, 26-33	48
463	CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. <b>2017</b> , 55, 123-131	15
462	Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. <b>2017</b> , 58, 104-109	12
461	The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. <b>2017</b> , 35, 357-364	
460	CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. <b>2017</b> , 22, 347-353	11
459	Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. <b>2017</b> , 105, 623-630	9
458	Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. <b>2017</b> , 31, 1234-1237	3
457	Frontline treatment of acute myeloid leukemia in adults. <b>2017</b> , 110, 20-34	68
456	Diagnostic work-up of acute myeloid leukemia. <b>2017</b> , 92, 317-321	14
455	Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. <b>2017</b> , 10, 51	62
454	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. <b>2017</b> , 10, 44	32
453	Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. <b>2017</b> , 141, 1342-1393	63
452	Aneuploidy in Cancer: Seq-ing Answers to Old Questions. <b>2017</b> , 1, 335-354	36
451	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 1333-1342	2.2 36
450	Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. <b>2017</b> , 98, 493-500	6
449	A novel recurrent copy number loss region on 6q23.3 in MDS-related myeloid malignancy patients with stable survival conditions. <b>2017</b> , 58, 2470-2479	0

448	Innovative strategies for adverse karyotype acute myeloid leukemia. <b>2017</b> , 24, 89-98	2
447	MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2. <b>2017</b> , 106, 258-265	28
446	Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. <b>2017</b> , 39, e254-e258	13
445	Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia. <b>2017</b> , 137, 195-200	3
444	Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia. <b>2017</b> , 1541, 223-245	14
443	BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype. <b>2017</b> , 99, 255-261	3
442	Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia. <b>2017</b> , 6, 384-388	3
441	Histamine and Histamine Receptors in Health and Disease. <b>2017</b> ,	3
440	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <b>2017</b> , 6, e1307491	24
439	Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience. <b>2017</b> , 59, 12-19	5
438	Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. <b>2017</b> , 23, 1447-1454	16
437	Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia. <b>2017</b> , 13, 3309-3313	1
436	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. <b>2017</b> , 59, 55-64	15
435	Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia. <b>2017</b> , 102, 1567-1577	24
434	Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. <b>2017</b> , 10, 18	5
433	Immunophenotyping and Cytogenetic/Molecular Genetic Analysis. <b>2017</b> , 69-134	
432	Acute Myeloid Leukaemia. <b>2017</b> , 135-248	
431	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 3165-3174 2.2	82

430	Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias. <b>2017</b> , 57, 112-118		21
429	Acute leukaemia. <b>2017</b> , 45, 280-286		0
428	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. <b>2017</b> , 96, 363-371		7
427	DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. <b>2017</b> , 129, 1-13		66
426	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 771-782	2.2	49
425	Chromosome-scale mega-haplotypes enable digital karyotyping of cancer aneuploidy. <b>2017</b> , 45, e162		22
424	Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. <b>2017</b> , 37, 1586-1599		11
423	Genetic, Hematologic and Psychological Aspects of Leukemia. <b>2017</b> , 667-755		1
422	Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish. <b>2017</b> , 7, e593		19
421	Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. <b>2017</b> , 68, 40-46		2
420	Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. <b>2017</b> , 60, 109-114		14
419	JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). <b>2017</b> , 106, 310-325		10
418	Return to work and work-related disability among AML survivors. <b>2017</b> , 96, 1625-1633		2
417	Azacitidine in adult patients with acute myeloid leukemia. <b>2017</b> , 116, 159-177		31
416	What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?: A Retrospective Analysis of 44 Patients With Serial SNP Arrays. <b>2017</b> , 147, 278-284		1
415	Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report. <b>2017</b> , 11, 94		2
414	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <b>2017</b> , 31, 1048-1058		8
413	Chromosomes and Chromosomal Instability in Human Cancer. <b>2017</b> , 241-262		

412	Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG). <b>2017</b> , 58, 889-897	8
411	Molecular biomarkers in acute myeloid leukemia. <b>2017</b> , 31, 63-76	126
410	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. <b>2017</b> , 31, 555-564	25
409	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. <b>2017</b> , 31, 1286-1295	39
408	Leukaemia. <b>2017</b> , 307-321	
407	FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. <b>2017</b> , 34, 300-306	11
406	Mutations in Inherited and Sporadic Leukemia. <b>2017</b> , 5, 111	44
405	Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges. <b>2017</b> , 23, 4303-4310	4
404	Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. <b>2017</b> , 10, 1585-1601	48
403	The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification. <b>2017</b> , 12, e0172029	2
402	DNA damage in acute myeloid leukemia patients of Northern Mexico. <b>2017</b> , 61, 2851	1
401	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. <b>2017</b> , 9, 227-234	21
400	Monosomal karyotype in myeloid neoplasias: a literature review. <b>2017</b> , 10, 2163-2171	10
399	Can we forecast induction failure in acute myeloid leukemia?. <b>2018</b> , 103, 375-377	4
398	Prevalence of Chromosome 7 Abnormalities in Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Single Center Study and Brief Literature Review. <b>2018</b> , 34, 602-611	3
397	Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics. <b>2018</b> , 57, 379-386	6
396	Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. <b>2018</b> , 57, 401-408	17
395	Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. <b>2018</b> , 63, 1-11	7

394	Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. <b>2018</b> , 139, 171-175	1
393	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. <b>2018</b> , 101, 86-94	19
392	High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype. <b>2018</b> , 68, 85-89	2
391	Myeloid Malignancies. <b>2018</b> , 397-421	1
390	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. <b>2018</b> , 59, 2394-2404	13
389	Clinical challenges in de novo pediatric acute myeloid leukemia. <b>2018</b> , 18, 277-293	16
388	ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics. <b>2018</b> , 59, 2439-2446	14
387	Myeloid Leukemia Vaccines. <b>2018</b> , 54-71	
386	The molecular signature of AML with increased ALDH activity suggests a stem cell origin. <b>2018</b> , 59, 2201-2210	9
385	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. <b>2018</b> , 66, 20-27	31
384	A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF $\beta$ in leukemic cells. <b>2018</b> , 59, 2188-2200	7
383	Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy. <b>2018</b> , 52, 439-445	8
382	Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. <b>2018</b> , 100, 198-205	8
381	Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21). <b>2018</b> , 108, 208-212	4
380	Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. <b>2018</b> , 21, 556-563	20
379	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. <b>2018</b> , 65, 67-73	9
378	Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. <b>2018</b> , 97, 1155-1167	9
377	Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study. <b>2018</b> , 18, 415-421	9

- 376 Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. **2018**, 197-236
- 375 Monitoring of post-transplant CFBF-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. **2018**, 180, 448-451 16
- 374 Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed AML. **2018**, 36, 252-257 8
- 373 A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. **2018**, 32, 263-272 25
- 372 DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. **2018**, 11, 82-89 16
- 371 Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. **2018**, 97, 51-61 11
- 370 Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. **2018**, 18, e19-e25 7
- 369 Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?. **2018**, 59, 521-522 2
- 368 Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study. **2018**, 59, 1323-1331 10
- 367 Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. **2018**, 97, 73-81 8
- 366 Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. **2018**, 173, 32-41 8
- 365 Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02. **2018**, 40, 43-47 14
- 364 Multiplex fusion gene testing in pediatric acute myeloid leukemia. **2018**, 60, 47-51 8
- 363 Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia. **2018**, 11, 47-53 1
- 362 KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. **2018**, 59, 829-836 13
- 361 Pharmacological inhibition of aberrant transcription factor complexes in inversion 16 acute myeloid leukemia. **2018**, 5, 30 1
- 360 Comparison of spatial chromosomal organization between bone marrow and peripheral blood in acute myeloid leukemia. **2018**, 16, 4656-4662
- 359 Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study. **2018**, 183, 618-628 4



358	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <b>2018</b> , 10,		5
357	The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies. <b>2018</b> , 30, 133-138		1
356	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <b>2018</b> , 32, 2546-2557		62
355	Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia. <b>2018</b> , 140, 183-192		15
354	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AML5G 17-10 CIARA trial). <b>2018</b> , 183, 235-241		2
353	Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. <b>2018</b> , 19,		30
352	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , <b>2018</b> , 132, 1703-1713	2.2	142
351	Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia. <b>2018</b> , 18, 122		14
350	A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia. <b>2018</b> , 49, 1589-1599		3
349	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. <b>2018</b> , 8, 87		20
348	Proteomics in Acute Myeloid Leukemia. <b>2018</b> ,		1
347	Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. <b>2018</b> , 73, 58-66		38
346	A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML. <b>2018</b> , 18, 21		1
345	KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia. <b>2018</b> , 108, 665-669		6
344	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <b>2018</b> , 11, 110		29
343	Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. <b>2018</b> , 2, 2513-2521		7
342	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. <b>2018</b> , 2, 964-968		12
341	Aberrant GSK3 $\beta$ nuclear localization promotes AML growth and drug resistance. <b>2018</b> , 2, 2890-2903		15

340	Recurrent mutations in -rearranged acute myeloid leukemia. <b>2018</b> , 2, 2879-2889		12
339	Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. <b>2018</b> , 11, 455-461		9
338	Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. <b>2018</b> , 65, e27231		6
337	Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. <b>2018</b> , 15, 121-126		19
336	Acute myeloid leukaemia. <b>2018</b> , 392, 593-606		280
335	Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2018</b> , 24, 2224-2232		8
334	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <b>2018</b> , 97, 1975-1985		3
333	Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. <b>2018</b> , 53, 25-34		8
332	Complex Karyotype in Hematological Diseases: A 6-Year Single Centre Study from Pakistan. <b>2018</b> , 2018, 2019239		1
331	A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes. <b>2018</b> , 42, 1495-1507		17
330	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <b>2018</b> , 93, 1142-1152		54
329	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. <b>2018</b> , 144, 1239-1251		5
328	An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. <b>2018</b> , 35, 95-110		16
327	Speciation Theory of Carcinogenesis Explains Karyotypic Individuality and Long Latencies of Cancers. <b>2018</b> , 9,		4
326	Treatment strategies for adolescent and young adult patients with acute myeloid leukemia. <i>Blood</i> , <b>2018</b> , 132, 362-368	2.2	15
325	Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco). <b>2018</b> , 105, 552-555		
324	Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association. <b>2019</b> , 33, 26-36		16
323	New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy. <b>2019</b> , 59, 361-377		12

322	MicroRNA-144 targets APP to regulate AML1/ETO leukemia cell migration via the p-ERK/c-Myc/MMP-2 pathway. <b>2019</b> , 18, 2034-2042	7
321	Acute Myeloid Leukemia: An Update. <b>2019</b> , 163-182	1
320	Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting. <b>2019</b> , 17, 827-839	1
319	Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. <b>2019</b> , 142, 58-67	11
318	TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. <b>2019</b> , 33, 2619-2627	9
317	Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia. <b>2019</b> , 12, 90	5
316	Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML). <b>2019</b> , 9, 1016	3
315	-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. <b>2019</b> , 8,	22
314	Assessing Measurable Residual Disease in Acute Myeloid Leukemia. <b>2019</b> , 2, 45-58	1
313	Prognostic hallmarks in AML. <b>2019</b> , 3, 847-849	
312	[What is recommended in the treatment of acute myeloid leukemia?]. <b>2019</b> , 60, 1240-1250	
311	Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. <b>2020</b> , 153, 251-257	
310	lncRNA-CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia. <b>2019</b> , 18, 2203-2211	11
309	Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. <b>2019</b> , 15, 3197-3208	11
308	A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. <b>2019</b> , 18, 567-578	6
307	Pediatric acute myeloid leukemia with t(7;21)(p22;q22). <b>2019</b> , 58, 551-557	3
306	RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia. <b>2019</b> , 20,	14
305	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <b>2019</b> , 12, 197-218	6

304	Stem Cells Heterogeneity in Cancer. <b>2019</b> ,	1
303	C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells. <b>2019</b> , 60, 3011-3019	
302	Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. <b>2019</b> , 1139, 153-169	9
301	Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. <b>2019</b> , 109, 673-683	4
300	Genomic profiling and predicting treatment response in acute myeloid leukemia. <b>2019</b> , 20, 467-470	7
299	Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. <b>2019</b> , 54, 2020-2026	1
298	Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?. <b>2019</b> , 15, 315-320	2
297	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <b>2019</b> , 46, 1902-1910	26
296	Molecular genetic testing methodologies in hematopoietic diseases: current and future methods. <b>2019</b> , 41 Suppl 1, 102-116	6
295	Genetic abnormalities and pathophysiology of MDS. <b>2019</b> , 24, 885-892	36
294	A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. <b>2019</b> , 3, 889-901	18
293	High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. <b>2019</b> , 234, 20322-20328	12
292	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <b>2019</b> , 216, 966-981	60
291	Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis. <b>2019</b> , 141, 164-175	8
290	Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. <b>2019</b> , 186, 300-310	4
289	Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. <b>2019</b> , 41, 461-471	4
288	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. <b>2019</b> , 33, 2575-2584	93
287	Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. <b>2019</b> , 8, 3	14

286	Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. <b>2019</b> , 109, 418-425		3
285	In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment. <b>2019</b> , 13, 18		4
284	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <b>2019</b> , 3, 1103-1117		11
283	Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. <b>2019</b> , 3, 1379-1393		6
282	Cytogenetics' impact on the prognosis of acute myeloid leukemia. <b>2019</b> , 11, 133-137		8
281	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. <b>2019</b> , 14, e0225977		4
280	CD105 (Endoglin) as negative prognostic factor in AML. <b>2019</b> , 9, 18337		12
279	The clinical and prognostic significance of FIS1, SPI1, PDCD7 and Ang2 expression levels in acute myeloid leukemia. <b>2019</b> , 233-234, 84-95		8
278	Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. <i>Blood</i> , <b>2019</b> , 133, 446-456	2.2	34
277	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <b>2019</b> , 25, 1737-1748		13
276	Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. <b>2019</b> , 76, 15-23		12
275	Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia. <b>2019</b> , 98, 351-359		13
274	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. <b>2019</b> , 285, 407-418		21
273	FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation. <b>2019</b> , 25, 941-948		9
272	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. <b>2019</b> , 125, 1091-1100		30
271	Management of primary refractory acute myeloid leukemia in the era of targeted therapies. <b>2019</b> , 60, 583-597		3
270	FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. <b>2019</b> , 60, 1014-1022		10
269	Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia. <b>2020</b> , 143, 9-18		5

268	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <b>2020</b> , 105, 414-423	3
267	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2020</b> , 105, 1723-1730	7
266	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥80 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <b>2020</b> , 55, 729-739	1
265	Detection of a novel CFBF-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). <b>2020</b> , 241, 72-76	1
264	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. <b>2020</b> , 34, 358-368	2
263	Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. <b>2020</b> , 240, 15-22	5
262	Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center. <b>2020</b> , 42, 37-45	
261	Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. <b>2020</b> , 143, 438-445	0
260	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <b>2020</b> , 95, 282-294	3
259	Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study. <b>2020</b> , 61, 820-830	9
258	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <b>2020</b> , 7, e122-e133	11
257	Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future. <b>2020</b> , 188, 29-35	2
256	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. <b>2020</b> , 4, 4623-4631	5
255	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/. <b>2020</b> , 117, 26340-26346	14
254	Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. <b>2021</b> , 21, 849-862	5
253	Mathematical Modeling Provides Evidence for Niche Competition in Human AML and Serves as a Tool to Improve Risk Stratification. <b>2020</b> , 80, 3983-3992	9
252	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. <b>2020</b> , 4, 3840-3849	4
251	Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. <b>2020</b> , 6, 1684-1695	7

250	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. <b>2020</b> , 95, 1361-1367	7
249	Machine learning derived genomics driven prognostication for acute myeloid leukemia with. <b>2020</b> , 61, 3154-3160	5
248	Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <b>2020</b> , 12,	3
247	Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy. <b>2020</b> , 42, 849-857	4
246	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <b>2020</b> , 26, 1995-2000	0
245	Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes. <b>2020</b> , 98, 106453	4
244	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <b>2020</b> , 22, 61	10
243	Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. <b>2020</b> , 112, 46-56	6
242	Novel Treatment Paradigms in Acute Myeloid Leukemia. <b>2020</b> , 108, 506-514	5
241	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. <b>2020</b> , 112, 200-209	4
240	Acute Myeloid Leukemia in Qatar (2010-2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes. <b>2020</b> , 11, 553	2
239	HMGA Proteins in Hematological Malignancies. <b>2020</b> , 12,	5
238	TXNIP induces growth arrest and enhances ABT263-induced apoptosis in mixed-lineage leukemia-rearranged acute myeloid leukemia cells. <b>2020</b> , 10, 1532-1541	6
237	Functional Classification of Mutations in Acute Myeloid Leukemia. <b>2020</b> , 12,	20
236	Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution. <b>2020</b> , 59, 396-405	0
235	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <b>2020</b> , 10, 26	14
234	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. <b>2020</b> , 98, 1069-1091	33
233	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <b>2020</b> , 34, 1577-1587	10



232	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. <b>2020</b> , 99, 501-511	28
231	The genomics of acute myeloid leukemia in children. <b>2020</b> , 39, 189-209	8
230	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. <b>2020</b> , 4, 1094-1101	26
229	Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <b>2020</b> , 12,	4
228	CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation. <b>2020</b> , 112, 57-64	3
227	Long-term outcome of childhood acute myeloid leukemia: A 10-year retrospective cohort study. <b>2020</b> , 12, 8486	3
226	Executable cancer models: successes and challenges. <b>2020</b> , 20, 343-354	23
225	Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. <b>2021</b> , 46, 100735	4
224	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. <b>2021</b> , 62, 399-409	0
223	Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation. <b>2021</b> , 62, 995-998	2
222	Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet. <b>2021</b> , 27, 173.e1-173.e9	2
221	Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 14, 134-140	0
220	High expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center. <b>2021</b> , 62, 185-193	1
219	Prognostic Factors in AML. <b>2021</b> , 127-175	1
218	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. <b>2021</b> , 100, 1203-1212	1
217	When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies. <b>2021</b> , 180, 85-117	0
216	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. <b>2021</b> , 231-250	
215	Advances in therapeutic options for newly diagnosed, high-risk AML patients. <b>2021</b> , 12, 20406207211001138	3

214	Computational reconstruction of clonal hierarchies from bulk sequencing data of acute myeloid leukemia samples.	
213	Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. <b>2021</b> , 147, 2659-2670	0
212	Concurrent Central Diabetes Insipidus and Acute Myeloid Leukemia. <b>2021</b> , 2021, 8898671	2
211	Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. <b>2021</b> , 5, 1003-1016	5
210	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. <b>2021</b> , 13,	5
209	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 256.e1-256.e7	2
208	Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethylators for acute myeloid leukemia. <b>2021</b> , 29, 5323-5327	6
207	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <b>2021</b> , 11, 46	1
206	Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. <b>2021</b> , 62, 1973-1981	0
205	The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. <b>2021</b> , 14, 303-314	0
204	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 100, 1267-1281	1
203	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <b>2021</b> , 56, 1908-1918	2
202	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. <b>2021</b> , 27, 311.e1-311.e10	0
201	Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. <b>2021</b> , 25, 299-309	1
200	miR-29c&b2 encourage extramedullary infiltration resulting in the poor prognosis of acute myeloid leukemia. <b>2021</b> , 40, 3434-3448	1
199	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <b>2021</b> , 56, 2445-2453	1
198	Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report. <b>2021</b> , 15, 228	0
197	Etiology of Acute Leukemia: A Review. <b>2021</b> , 13,	6

196	Cytogenetic and mutational analysis and outcome assessment of a cohort of 284 children with de novo acute myeloid leukemia reveal complex karyotype as an adverse risk factor for inferior survival. <b>2021</b> , 14, 27	0
195	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <b>2021</b> , 11, 92	1
194	The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft. <b>2021</b> , 56, 2284-2286	
193	Core binding factor acute myelogenous leukemia-2021 treatment algorithm. <b>2021</b> , 11, 114	9
192	Cytogenetic influence on prognosis in acute promyelocytic leukaemia: A cohort study in Vietnam. <b>2021</b> ,	0
191	Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). <b>2021</b> , 21, e635-e643	
190	Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. <b>2021</b> , 100, 2387-2398	1
189	Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. <b>2021</b> , 1	0
188	Interferon- $\gamma$ maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. <b>2021</b> , 62, 2949-2956	3
187	Computational Reconstruction of Clonal Hierarchies From Bulk Sequencing Data of Acute Myeloid Leukemia Samples. <b>2021</b> , 12, 596194	0
186	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. <b>2021</b> , 10,	1
185	Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. <b>2021</b> , 35, 3073-3077	0
184	The relationship between emotional well-being and understanding of prognosis in patients with acute myeloid leukemia (AML). <b>2022</b> , 30, 897-906	0
183	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. <b>2021</b> ,	2
182	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. <b>2022</b> , 69, e29341	0
181	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <b>2021</b> , 1-5	1
180	TIM-3 in Leukemia; Immune Response and Beyond. <b>2021</b> , 11, 753677	3
179	Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia. <b>2021</b> , 14, 45	1

178	Frequency of FLT3 Internal tandem duplication (ITD) gene mutations in various cytogenetic groups in acute myelogenous leukemia (AML): A report from Tamil Nadu, India. <b>2021</b> , 25, 101310	
177	CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia. <b>2021</b> , 55, 121-132	
176	Genomic Landscape and Clonal Evolution of AML. <b>2021</b> , 103-118	
175	In vivo evaluation of leukemic stem cells through the xenotransplantation model. <b>2008</b> , Chapter 3, Unit 3.2	2
174	Acute myeloid leukemia. 62-125	2
173	Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia. 115-124	1
172	Acute Myeloid Leukemia and the Myelodysplastic Syndromes. <b>2006</b> , 1160-1181	1
171	Applying GCS Networks to Fuzzy Discretized Microarray Data for Tumour Diagnosis. <b>2006</b> , 1095-1102	4
170	Akute lymphoblastische Leukämien. <b>2006</b> , 656-679	1
169	Microarrays for cancer diagnosis and classification. <b>2007</b> , 593, 74-85	51
168	Immunotherapy of AML. <b>2010</b> , 145, 237-55	2
167	Molecular Evolution of Leukemia Stem Cells. <b>2013</b> , 449-458	1
166	Impact of Cytogenetics on Clinical Outcome in AML. <b>2007</b> , 177-192	14
165	Fluorescence In situ hybridization (FISH) as a tool for the detection of significant chromosomal abnormalities in childhood leukaemia. <b>2009</b> , 538, 29-55	2
164	Epigenetics in myeloid malignancies. <b>2012</b> , 863, 119-37	7
163	Acute Myeloid Leukemia: Epidemiology and Etiology. <b>2008</b> , 47-56	7
162	Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients. <b>2014</b> , 145, 189-214	2
161	Genomics in Leukemias. <b>2009</b> , 844-855	1

160	Acute Myeloid Leukemia in Adults. <b>2008</b> , 2215-2234	1
159	Myelodysplastic Syndromes. <b>2008</b> , 2235-2259	1
158	Molecular Diagnosis in Hematopathology. <b>2011</b> , 56-80	2
157	Cytogenetic and Molecular Pathology of Pediatric Cancer. <b>2009</b> , 99-171	1
156	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. <b>2009</b> , 331-402	1
155	Childhood Leukemia. <b>2014</b> , 1849-1872.e11	4
154	Myelodysplastic syndrome. 548-570	1
153	Therapy-related leukemias. 774-804	1
152	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. <b>2000</b> , 111, 190-5	227
151	Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia. <b>2000</b> , 111, 570-9	5
150	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <b>2000</b> , 111, 801-6	104
149	Molecular diagnostics in the treatment of leukemia. <b>1999</b> , 6, 229-35	15
148	A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. <b>2007</b> , 117, 2611-20	93
147	Chromosomal instability and cancer: a complex relationship with therapeutic potential. <b>2012</b> , 122, 1138-43	169
146	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. <i>Blood</i> , <b>2000</b> , 96, 870-877	2.2 3
145	Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia. <b>2017</b> , 1, 2120-2123	8
144	STAT3 is a tumor suppressor in acute myeloid leukemia. <b>2019</b> , 3, 1989-2002	13
143	Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats. <b>2012</b> , 7, e33213	50

142	High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. <b>2012</b> , 7, e51527	48
141	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. <b>2013</b> , 8, e65998	27
140	Gene expression profiles associated with pediatric relapsed AML. <b>2015</b> , 10, e0121730	20
139	High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia. <b>2015</b> , 10, e0124241	24
138	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. <b>2016</b> , 7, 62377-62385	10
137	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <b>2017</b> , 8, 49548-49563	23
136	, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. <b>2017</b> , 8, 76003-76014	5
135	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <b>2018</b> , 9, 4961-4968	13
134	An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. <b>2015</b> , 6, 39098-110	31
133	Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. <b>2012</b> , 3, 824-32	19
132	HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia. <b>2016</b> , 7, 3623-34	7
131	Comparison of total body irradiation-based or non-total body irradiation-based conditioning regimens for allogeneic stem cell transplantation in pediatric leukemia patients. <b>2010</b> , 53, 538	8
130	Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia. <b>2016</b> , 129, 1355-62	3
129	Current Cytogenetic Abnormalities in Acute Myeloid Leukemia.	0
128	Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. <b>2014</b> , 15, 1247-53	23
127	Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review. <b>2014</b> , 15, 1603-9	10
126	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. <b>2021</b> ,	1
125	Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia. <b>2021</b> , 21, 526	1

- 124 Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.
- 123 Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia. **2001**, 578-587
- 122 Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia **2001**, 470-476
- 121 Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor. **2001**, 172-175
- 120 Stellenwert molekularbiologischer Verfahren in der klinischen Hämatologie und Onkologie. **2001**, 345-361
- 119 Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities. **2001**, 330-338
- 118 Mechanisms of Chromosomal Translocation Breakpoints. **2001**, 3-10
- 117 Real-Time RT-PCR for the Detection and Quantification of AML1/MTG8 Fusion Transcripts in Patients with t(8;21) Positive AML. **2001**, 34-39
- 116 Quantitative Analysis of AML1-ETO Fusion Transcripts in t(8;21) Positive AML Using Real-Time RT-PCR. **2002**, 159-168 1
- 115 Protocol for the examination of specimens from patients with hematopoietic neoplasms of the bone marrow: a basis for checklists. **2002**, 126, 1050-6 12
- 114 Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach. **2003**, 377-380
- 113 Outcome of Patients with Refractory/Recurrent Acute Myelogenous Leukaemia (AML) Treated at a Single Centre. **2003**, 407-411
- 112 Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia. **2003**, 128-135
- 111 Akute myeloische Leukämien. **2003**, 312-350
- 110 Myelodysplastische Syndrome. **2003**, 268-311
- 109 Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia. **2003**, 312-320
- 108 Transplantation Strategies for High Risk Acute Myeloid Leukemias. **2003**, 469-472
- 107 Weekly Oral Idarubicin: An Ambulatory Treatment of Acute Myeloid Leukemia in Poor-Risk Elderly Patients. **2003**, 426-430



106 Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14th Day of Induction Treatment. **2003**, 321-326

105 Akute Leukämien. **2003**, 1047-1055

104 Real-Time Quantification of the AML Rearrangements, AML1-ETO and TEL-AML1, in Acute Leukemia. **2004**, 141-155

103 Myeloid Malignancies.

102 Acute myeloid leukemia in children and adolescents. **2004**, 617-632

101 References. **2004**, 379-401

100 FISH Blood and Bone Marrow. **2004**, 461-467

99 Acute Leukemia. **2005**, 1-17

1

98 Akute myeloische Leukämie (AML). **2006**, 2605-2645

97 Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents. **2007**, 345-372

96 Stem Cell Transplantation for AML. **2007**, 313-327

95 APL: A Classic Tale of Bench to Bedside. **2007**, 193-228

94 AML in Older Adults. **2007**, 373-384

93 Childhood Leukemia. **2008**, 2139-2169

1

92 Hematologic malignancies: correlation between morphology, phenotype,. **2008**, 125-242

91 Gene Expression Profiling of the Leukemias: Oncogenesis, Drug Responsiveness, and Prediction of Clinical Outcome. **2009**, 1-19

90 Leukemic Stem Cells: New Therapeutic Targets?. **2009**, 519-526

89 Infant Leukemias. **2009**, 403-416

1

- 88 Therapy of acute myelogenous leukemia in adults. **2010**, 145, 257-71
- 87 The Role of Transplantation in Favorable-Risk Acute Myeloid Leukemia. **2010**, 177-192
- 86 Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. **2009**, 3, E14-E24
- 85 Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance. **2010**, 89-113
- 84 Retrospective Analysis of 50 Cases of First Allogeneic Transplantation for Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome. **2010**, 59, 105-113
- 83 Acute Myelogenous Leukemia. **2010**, 601-605
- 82 Treatment of Acute Myeloid Leukemia. **2011**, 121-160 1
- 81 Strategies for New Agent Development and Clinical Trial Considerations. **2011**, 215-241
- 80 Biology of Acute Myeloid Leukemia. **2011**, 63-76 1
- 79 Current Status of BoneMarrow Transplantation for Treatment of Cancer. **2011**, 407-435
- 78 Non-Cytogenetic Markers and their Impact on Prognosis. 56-76
- 77 Cytogenetic analysis in acute myeloid leukaemia. **2011**, 730, 63-77
- 76 Diagnostics particuliers. **2011**, 39-64
- 75 Acute Myeloid Leukemia. 103-126
- 74 Immunophenotyping and Cytogenetic/Molecular Genetic Analysis in Leukaemia and Related Conditions. 64-113
- 73 Acute Leukaemia: Integration of Morphological, Immunophenotypic and Genetic Information and the WHO Classification. 114-218
- 72 Tumours of the Immune System.
- 71 Pharmacogenomics in Acute Myeloid Leukemia. **2013**, 237-248 1

- 70 Non-myeloablative allogeneic stem cell transplantation versus standard stem cell transplantation for haematological malignancies.
- 69 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2
- 68 Molecular Testing in Hematologic Malignancies. **2014**, 135-167
- 67 Acute Leukemias in Adults. **2014**, 1890-1906
- 66 Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia. **2012**, 29-53
- 65 Cytogenetics: Applications. **2016**, 67-82
- 64 Outcomes of Hematopoietic Stem Cell Transplantation by Donor Types in Children with Acute Myeloid Leukemia. **2016**, 23, 145-157
- 63 Molecular Monitoring of RUNX1-RUNX1T1 Transcript Level in Acute Myeloblastic Leukemias on Treatment. **2016**, 9, 456-464 2
- 62 Indications for Hematopoietic Stem Cell Transplantation in Children. **2018**, 55-81
- 61 De novo acute myeloid leukemia with t(8;21)(q22;q22) and monosomy 7. **2019**, 10, 99
- 60 OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH ACTIVE DISEASE IN ACUTE MYELOID LEUKEMIA. **2020**, 15, 15
- 59 CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. **2021**, 13, 1
- 58 Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia. **2020**, 65, 444-459
- 57 Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies. **2020**, 383-533 1
- 56 Leukemic Stem Cells: New Therapeutic Targets?. **2009**, 215-230
- 55 Therapy of AML. **2008**, 1-20
- 54 Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the Myelodysplastic Syndromes in AML Pathogenesis). **2008**, 21-46 1
- 53 Special Diagnostics. **2008**, 39-64

- 52 Acute Myeloid Leukemia: Epidemiology and Etiology. **2021**, 3-9
- 51 Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients' prognosis. **2020**, 146, 3097-3109 ○
- 50 Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. **2021**, 3
- 49 Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. **2021**, 13,
- 48 Monosomal karyotype as an adverse risk factor for inferior survivals in children with acute myeloid leukemia. **2021**, 6, 158-158
- 47 Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. **2021**, ○
- 46 The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.. **2021**, ○
- 45 Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.. **2022**,
- 44 Gene Mutations, rs16754 Variant, and Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients.. **2022**, 11,
- 43 BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults.. **2022**, 95, 102662 1
- 42 Genetic Profiles and Risk Stratification in Adult De Novo Acute Myeloid Leukaemia in Relation to Age, Gender, and Ethnicity: A Study from Malaysia.. **2021**, 23,
- 41 Molecular Risk Stratification using Next-generation Sequencing in Acute Myeloid Leukemia. **2021**, 96, 493-500
- 40 Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.. **2022**, 1 ○
- 39 Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.. **2022**, ○
- 38 Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy.. **2022**,
- 37 Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.. **2022**, ○
- 36 Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.. **2022**, 1-11 ○
- 35 Mutation rates and fitness consequences of mosaic chromosomal alterations in blood.

- 34 Efficacy of conventional-dose cytarabine, idarubicin and thioguanine (IAT) versus intermediate-dose cytarabine and idarubicin (IdAraC-Ida) in the induction treatment of AML: long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
- 33 The Emerging Roles of Aldehyde Dehydrogenase in Acute Myeloid Leukemia and its Therapeutic Potential. **2022**, 22,
- 32 Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma. **2022**, 17, e0269570 1
- 31 Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines From the American Society of Transplantation and Cellular Therapy. **2022**,
- 30 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. **2022**, 15, 0
- 29 Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML. 0
- 28 Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia. 0
- 27 The mythological chimera and new era of relapse prediction post-transplant. **2022**, 100997 0
- 26 Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. 12, 0
- 25 The Role of RNA-Binding Proteins in Hematological Malignancies. **2022**, 23, 9552 0
- 24 Therapeutic applications of toll-like receptors (TLRs) agonists in AML. 0
- 23 Leukemias, Lymphomas, and Plasma Cell Disorders. **2023**, 237-300
- 22 Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia. **2022**, 122, 106954 0
- 21 Clinical Application of Biomarkers for Hematologic Malignancies. **2022**, 150-212 0
- 20 Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. 1-12 0
- 19 Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. **2022**, 13, 0
- 18 How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. **2022**, 58, 1386 0
- 17 Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. 0

- 16 The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia. **2022**, 1-14 ○
- 15 Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico. ○
- 14 The Pattern of Chromosome Aberrations and Molecular Markers in the Population of Hematological Patients Diagnosed at the University Clinical Center Tuzla. **2022**, 4, 93-97 ○
- 13 The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. **2023**, 15, 198 ○
- 12 High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia. **2023**, 15, 296 ○
- 11 Genomics and Diagnostics in Acute Myeloid Leukaemia. **2019**, 161-185 ○
- 10 Clinical Impact of c-KIT and CEBPA Mutations in 33 Patients with Corebinding Factor (Non-M3)Acute Myeloid Leukemia. **2023**, ○
- 9 Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study. 13, ○
- 8 Allogeneic hematopoietic cell transplantation in acute myeloid leukemia. **2023**, 36, 101466 ○
- 7 Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis. ○
- 6 Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. **2023**, 37, 788-798 ○
- 5 Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia. **2023**, 24, 4440 ○
- 4 Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study. ○
- 3 The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience. **2023**, 59, 498 ○
- 2 DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. **2023**, 329, 745 ○
- 1 The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML. ○